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ABSTRACT 
Title: Mechanisms of Hdac2 function in the regulation of adult cardiac hypertrophy 
and embryonic myocyte proliferation 
Wenting Zhu 
Jonathan A. Epstein 
HDACs can modify the structure and function of chromatin to regulate gene 
expression and can also modify many non-histone proteins that regulate cell function 
and signaling. HDACs have attracted increasing interest because they are involved in 
a variety of physiologic and pathophysiologic processes including stem cell 
maintenance, differentiation, cancer, inflammation and cardiac diseases. In the 
absence of Hdac2, mice display myocyte hyper-proliferation during embryonic 
development and resistance to cardiac hypertrophy in adulthood. This doctoral 
dissertation examines the function of two Hdac2 downstream targets, Inpp5f and 
Gata4, in regulating adult cardiac hypertrophy and embryonic myocyte proliferation, 
respectively. My results suggest that Inpp5f is an important endogenous modulator of 
the cardiac response to stress. I also performed studies to show that, in the absence of 
Hdac2 in the embryonic heart, hyper-acetylated Gata4 is responsible for myocyte 
hyper-proliferation. These findings provide a framework for understanding the role of 
Hdac2 in embryonic heart development and adult cardiac diseases. 
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Chapter 1 Introduction 
In this dissertation, I explore the mechanisms of histone deacetylase 2 (Hdac2) 
in regulating adult cardiac hypertrophy and embryonic cardiomyocyte proliferation. 
Previous work suggests that Hdac2 promotes hypertrophy associated with increased 
phosphoinositide 3-kinase (PI3K)/Akt signaling and Hdac2 negatively regulates the 
expression of a novel phosphoinositide 5-phosphatase, inositol polyphosphate-5-
phosphatase 5 F (Inpp5f) (Trivedi et al., 2007). The activity of this protein is specific 
for PtdIns(4,5)P2 and PtdIns(3,4,5)P3 (Minagawa et al., 2001). In chapter 2, I 
describe experiments to study the role of Inpp5f in regulating hypertrophy. These 
studies led to the discovery that Inpp5f is an important endogenous modulator of 
cardiac responses to stresses and it regulates the hypertrophy process through 
regulating the PI3K/Akt pathway. Another interesting phenotype of Hdac2 knockout 
mice is hyper-proliferation of myocytes during embryonic development. In chapter 3, 
I investigated the role of Hdac2 in regulating GATA-binding factor 4 (Gata4), a 
crucial regulator of cardiomyocytes proliferation (Rojas et al., 2008; Zeisberg et al., 
2005). This introductory chapter will summarize our current knowledge of PI3K/Akt 
signaling during cardiac hypertrophy, Gata4 function during heart development and 
other areas of interest related to my thesis project.   
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1.1 Cardiac hypertrophy 
Cardiovascular disease remains the number one cause of mortality in the 
Western world, with heart failure representing the fastest growing subclass over the 
past decade (Heineke and Molkentin, 2006; Hobbs, 2004; Kannel, 2000; Levy et al., 
2002). For example, there are approximately 5 million Americans currently diagnosed 
with heart failure, which is characterized by a 5-year survival rate of approximately 
50%, resulting in a total economic impact as high as 100 billion dollars per year 
(Heineke and Molkentin, 2006). 
Cardiac hypertrophy is an early milestone during the clinical course of heart 
failure and an important risk factor for subsequent cardiac morbidity and mortality 
(Hunter and Chien, 1999). During cardiac hypertrophy, individual myocytes grow in 
length and/or width as a means of increasing cardiac pump function and decreasing 
ventricular wall tension (Heineke and Molkentin, 2006). Although hypertrophy is 
initially beneficial, permitting enhanced cardiac output, it can ultimately become 
deleterious and result in cardiomyopathy, heart failure and sudden death (McKinsey 
and Olson, 1999). It can occur in response to normal physiological stimuli, as during 
pregnancy and exercise, or may be associated with disease-inducing stimuli leading to 
cardiac dilatation and congestive heart failure (Frey and Olson, 2003). The defining 
features of hypertrophy are an increase in cardiomyocyte size, enhanced protein 
synthesis, and a higher organization of the sarcomere. It is not accompanied by cell 
proliferation or cardiac cell renewal. The changes in cellular phenotype are preceded 
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and accompanied by the reinduction of the so-called fetal gene program, including 
natriuretic peptide precursor type A (Nppa) (encoding atrial natriuretic factor, ANF), 
Myh7(encoding β-myosin heavy chain), and Nppb (encoding BNP) (Frey and Olson, 
2003).  
Cardiac hypertrophy requires coupling of intracellular signal transduction 
systems with transcription factors that activate and maintain the hypertrophic program 
(McKinsey and Olson, 1999). Over the past years, signaling pathways involving 
growth factors, G proteins, mitogen-activated protein kinases and calcium-responsive 
phosphatases have emerged as critical regulators of cardiac hypertrophy (Dorn and 
Force, 2005; Gupta et al., 2007; McKinsey and Olson, 1999). The PI3K/Akt signaling 
network is of particular interest because many components in this pathway have been 
shown to modulate myocyte survival, hypertrophy, contractility, electrophysiology, 
metabolism, mechanotransduction and coronary angiogenesis (Oudit and Penninger, 
2009). The following sections will describe these in detail and discuss the 
experimental data supporting a role for the PI3K/Akt pathway in the hypertrophic 
process. 
Another particularly important phenomenon involved in gene expression is 
histone acetylation/deacetylation which is mediated by histone acetyl transferase 
(HAT) and HDAC (Ekwall, 2005). The balance between HAT and HDAC seems to 
play an especially important role in the control of gene expression, which, according 
to recent evidence, will also affect the hypertrophic process (Antos et al., 2003; Chang 
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et al., 2004; Kong et al., 2006; Kook et al., 2003; Montgomery et al., 2007; Trivedi et 
al., 2007; Zhang et al., 2002).  
Despite all the current knowledge of hypertrophy, the cellular mechanisms that 
regulate the hypertrophic response to agonists or to stretch remain poorly understood, 
and treatments to combat hypertrophy are also lacking. My study will be directly 
relevant for the development of new therapies for cardiac hypertrophy and heart 
failure that target intrinsic abnormalities in signaling pathways and transcriptional 
programs within the diseased cardiac myocyte. 
 
1.2 Overview of the PI3K/Akt signaling pathway 
The PI3K/Akt signaling network (outlined in Figure 1.1) is crucial to widely 
divergent physiological processes that include cell cycle progression, differentiation, 
transcription, translation, apoptosis and metabolism (Martelli et al., 2006). PI3K can 
be activated by several receptor tyrosine kinases (RTKs), such as the insulin growth 
factor-1 (IGF-1) receptor (Walsh, 2006), as well as G protein-coupled receptors 
(GPCRs), including α- (Schluter et al., 1998) and β2-adrenergic receptors (Chesley et 
al., 2000; Zhu et al., 2001). Upon ligand binding, PI3K is translocated to the 
membrane, where it converts the plasma-membrane lipid phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2, PIP2) to phosphatidylinositol-3,4,5-trisphosphate 
(PtdIns(3,4,5)P3, PIP3). PIP3 then recruits both Akt/protein kinase B (PKB) and its 
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activator phosphoinositide-dependent protein kinase-1 (PDK1) to the membrane by 
binding to their pleckstrin homology (PH) domains, leading to phosphorylation and 
activation of Akt (Matsui et al., 2003). Activation of Akt then leads to activation of 
mammalian target of rapamycin (mTOR), a central regulator of protein synthesis. Akt 
also phosphorylates and inhibits a kinase, glycogen synthase kinase 3β (Gsk3β) (Dorn 
and Force, 2005).  
The PI3K/Akt pathway is highly regulated. The termination of PI3K/Akt 
signaling by degradation of PtdIns(3,4,5)P3 can be mediated by at least two different 
types of phosphatases,  3-ptases (inositol polyphosphate 3-phosphatases), which 
converts PtdIns(3,4,5)P3 back to PtdIns(4,5)P2, and 5-ptases (inositol polyphosphate 
5-phosphatases), which generates PtdIns(3,4)P2 (Ooms et al., 2009).  
 
1.3 Inositol polyphosphate phosphatases 
Phosphoinositides (PIs) are quantitatively minor phospholipids of cell 
membranes but their metabolism is highly active and accurately controlled by specific 
PI kinases and phosphatases (Pendaries et al., 2003). The importance of these PI 
phosphatases in cell regulation is illustrated by their involvement in human diseases 
such as cancer and diabetes (Blero et al., 2007) (Table 1.1). Cellular levels of 
PtdIns(3,4,5)P3 are about 50 nM in unstimulated cells but increase 40 fold within 
seconds to within 2 µM following agonist stimulation (Insall and Weiner, 2001; 
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Stephens et al., 1993). PtdIns(3,4,5)P3 is dephosphorylated within seconds by 
phosphatases.  The most well-studied PtdIns(3,4,5)P3 3-ptase is PTEN (phosphatase 
and tensin homolog deleted on chromosome ten) (Cantley, 2002; Oudit et al., 2004), 
while the 5-ptases are a large family comprising 10 mammalian and 4 yeast members 
(Astle et al., 2006). 
1.3.1 PTEN 
PTEN was first identified as tumor suppressor gene localized on chromosome 
10q23 (Li et al., 1997; Steck et al., 1997). Human germline mutations in PTEN are 
associated with several rare autosomal dominant cancer predisposition syndromes 
including Cowden disease (Knobbe et al., 2008; Liaw et al., 1997; Marsh et al., 1998) 
(Table 1.1). Mice homozygous for targeted deletions within the PTEN gene (PTEN -/-) 
die during embryonic development (between Days 6.5 and 9.5), while heterozygous 
mice develop normally but are prone to a wide range of tumor types including cancers 
of the breast, thyroid, endometrium and prostate as well as T cell lymphomas (Di 
Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic et al., 1998; Suzuki et al., 
1998). PTEN +/- mice also develop signs of autoimmune disease (Di Cristofano et al., 
1999).  
The main physiological substrates of PTEN are PtdIns(3,4,5)P3 and possibly 
PtdIns(3,4)P3. PTEN is considered the principal regulator of basal cellular 
PtdIns(3,4,5)P3 levels (Leslie and Downes, 2002). A lot of studies using PTEN null 
cell lines have been done to study the effects of PTEN activity on cellular 
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PtdIns(3,4,5)P3 (Leslie and Downes, 2002; Maehama and Dixon, 1998; Stambolic et 
al., 1998; Sun et al., 1999). Deletion of PTEN in murine fibroblasts and embryonic 
stem cells results in greatly elevated unstimulated PtdIns(3,4,5)P3 levels (Stambolic et 
al., 1998; Sun et al., 1999). Similar results have also been obtained with human tumor 
cell lines lacking PTEN, and PtdIns(3,4,5)P3 levels are reduced dramatically upon re-
expression of the phosphatase (Taylor et al., 2000). HPLC analysis of labeled cellular 
PIs has also shown that PtdIns(3,4)P2 levels appear similarly high and decrease with 
PTEN re-expression (Taylor et al., 2000). In addition to this direct evidence, a wealth 
of data has shown greatly increased activity of the downstream kinase Akt in many 
PTEN null cell types, and that this activity is reduced by expression of PTEN (Haas-
Kogan et al., 1998; Li and Sun, 1998; Li et al., 1998; Myers et al., 1998; Nakashima 
et al., 2000; Persad et al., 2000; Ramaswamy et al., 1999; Stambolic et al., 1998; Sun 
et al., 1999; Wu et al., 1998). Cardiac specific PTEN knockout mice have also been 
generated (Crackower et al., 2002) and the detailed phenotypes will be reviewed later. 
1.3.2 Inositol polyphosphate 5-phosphatases 
1.3.2.1 Src homology 2 (SH2) domain-containing inositol polyphosphophate 5-
phosphatases 1 and 2 (SHIP and SHIP2) 
SHIP and SHIP2 are capable of removing the 5-phosphate from PtdIns 
(3,4,5)P3 to yield PtdIns (3,4)P2. SHIP is expressed predominantly in hematopoietic 
cells where it is an important negative regulator of cytokine signaling. SHIP-/- mice 
have shorter life span associated with massive myeloid cell infiltration of the lungs 
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and numerous hematopoietic abnormalities (Helgason et al., 1998; Liu et al., 1998). 
SHIP2 is more widely expressed, most highly in brain, skeletal muscle and heart 
(Astle et al., 2006). It plays an important role in insulin signaling and obesity 
regulation (Grempler et al., 2007; Sleeman et al., 2005). When exposed to a normal 
diet, SHIP2-/- mice exhibit a basal metabolic rate similar to wild type controls 
However, SHIP2-/- mice are highly resistant to weight gain when placed on a high-fat 
diet. Under these conditions, SHIP2-/- mice demonstrate an increased metabolic rate 
and show no increase in serum lipids, insulin or glucose levels. The liver and skeletal 
muscle of the SHIP2-/- mice shows evidence of enhanced activation of the Akt 
signaling pathway (Sleeman et al., 2005). Genotypic analyses of diabetic rat and 
human subjects have found a significant association between SHIP2 gene 
polymorphisms and type 2 diabetes (Kagawa et al., 2005; Kaisaki et al., 2004; Marion 
et al., 2002).  
1.3.2.2 Synaptojanin 1/2 
Two synaptojanin isoforms (1 and 2) are 5-phosphatases which are able to 
hydrolyze PtdIns(3,4,5)P3 and PtdIns(4,5)P2 (McPherson et al., 1996; Woscholski et 
al., 1997). Synaptojanin 1 is a nerve terminal protein of 145 kDa that appears to 
participate with dynamin in synaptic vesicle recycling (McPherson et al., 1996). 
Synaptojanin 1-deficient mice die shortly after birth due to neurological defects 
(Cremona et al., 1999). Linkage analysis for bipolar disorder identified synaptojanin 1 
as a candidate gene (Saito et al., 2001; Stopkova et al., 2004). The cDNA encoding 
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Synaptojanin 2 was identified by polymerase chain reaction using degenerate primers 
(Nemoto et al., 1997). It regulates the early stages of endocytosis. Depletion of 
synaptojanin 2 in A-549 cells causes a decrease in the number and size of vesicles at 
all stages of endocytosis (Rusk et al., 2003). Targeted depletion of synaptojanin 2 in 
glioblastoma cells also inhibits the formation of lamellipodia and invadopodia, and 
cell migration and invasion (Chuang et al., 2004).  
Both Synaptojanin 1 and 2 have a Sac domain, which contains phosphatase 
activity (Guo et al., 1999). The Sac domain has approximately 400 amino acid 
residues and is defined by seven conserved motifs which appear to define the catalytic 
and regulatory regions of the phosphatase (Hughes et al., 2000). The highly conserved 
sequence RXNCXDCLDRTN in the sixth motif is proposed to be the catalytic core of 
the Sac domain phosphatases. The CX5R(T/S) motif within this sequence is also 
found in a number of metal-independent protein phosphatases and inositol 
polyphosphate phosphatases and is known to be a phosphatase catalytic site (Guo et 
al., 1999; Hughes et al., 2000). Interestingly, the Sac domain of the yeast 
synaptojanin-like protein Inp51p does not exhibit phosphatase activity, and the 
cysteine, arginine and threonine/serine residues are absent from the CX5R(T/S) motif 
of this protein, being replaced by alanine, lysine and proline respectively. Furthermore, 
mutations of the first conserved aspartate residue in the RXNCXDCLDRTN sequence 
as seen in the yeast sac1-8 and sac1-22 mutant alleles were demonstrated to inactivate 
the Sac1p functions (Hughes et al., 2000; Kearns et al., 1997; Zhong and Ye, 2003). 
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Together, this evidence suggests that the RXNCXDCLDRTN motif could well 
represent the catalytic core of the Sac phosphatases. 
1.3.2.3 Inositol polyphosphate-5-phosphatase F (Inpp5f) 
Inpp5f is a novel Sac domain-containing phosphoinositide 5-phosphatase whose 
activity is specific for PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in vitro (Minagawa et al., 
2001). As I will discuss later in the next chapter, I was able to identify the seven 
conserved motifs and the sixth conserved region of Inpp5f in both mouse and human 
has the highly conserved CX5R(T/S) motif, suggesting it is catalytically active. It is 
widely expressed in several tissues including brain, heart, skeletal muscle, kidney 
(Minagawa et al., 2001). However, its in vivo role has not been characterized prior to 
this study. 
 
1.4 PI3K/Akt signaling in cardiac hypertrophy 
The PI3K/Akt pathway is essential for both basal cell growth as well as 
adaptive (physiologic) and maladaptive (pathologic) hypertrophy (Oudit et al., 2004). 
Several transgenic and knockout models support a fundamental role of this pathway in 
the regulation of hypertrophy (Summarized in Table 1.2).  
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1.4.1 PI3K 
PI3K inhibitors attenuate basal rates of protein synthesis in unstimulated cells 
and abolish increases in protein synthesis induced by insulin in neonatal 
cardiomyocytes (Pham et al., 2000). The complete knockout of p110α, the catalytic 
subunit of PI3Kα, was lethal at E9.5-E10.5 due to a severe proliferation defect (Bi et 
al., 1999) and therefore was of limited usefulness for cardiac studies. Cardiac specific 
over-expression of constitutively active PI3Kα (CA-PI3Kα) in mice results in 
enlarged hearts owing to increased cardiomyocyte size (Crackower et al., 2002; Shioi 
et al., 2000), whereas over-expression of dominant negative PI3Kα (DN-PI3Kα) 
produces smaller hearts with reduced cardiomyocyte size without affecting cell 
number (Crackower et al., 2002; McMullen et al., 2003; Shioi et al., 2000). These 
changes in heart size are associated with corresponding alterations in Akt, and p70S6-
kinase (p70S6K) phosphorylation and activities. These studies suggest a positive role 
of PI3K in cardiac growth. 
1.4.2 PDK1 
PDK1 is a ubiquitously expressed 67 kDa kinase containing a N-terminal 
catalytic domain and a C-terminal PH domain (Storz and Toker, 2002; Toker and 
Newton, 2000). It is central in the PI3K signaling pathway and whole-body knockout 
of PDK1 is associated with embryonic lethality (Lawlor et al., 2002) while cardiac 
specific PDK1 ablation leads to reduced cardiomyocyte size and cardiomyopathy (Ito 
et al., 2009; Mora et al., 2003).     
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1.4.3 Akt/PKB 
Akt is a serine/threonine protein kinase family comprising three closely related, 
highly conserved isoforms: Akt1 (PKBα), Akt2 (PKBβ) and Akt3 (PKBγ) (Chan et al., 
1999; Oudit and Penninger, 2009). Akt2 and Akt3 show 81 and 83% amino acid 
identity, respectively, with Akt1 (Shioi et al., 2002). Only Akt1 and Akt2 are highly 
expressed in the heart (Dorn and Force, 2005). The activity of Akt is primarily 
controlled by PI3K and PTEN via the modulation of PtdIns(3,4,5)P3 levels (Maehama 
et al., 2001; Stambolic et al., 1998; Vanhaesebroeck et al., 2001) 
Several Akt knockout and transgenic mouse models have been generated to 
study the physiological roles of Akt. Targeted disruption of the Akt1 gene in mice 
results in a growth retardation phenotype. They have a 20% reduction in body size, 
with a concomitant reduction in heart size (Chen et al., 2001; Cho et al., 2001b). More 
recently, Akt1 null mice were shown to be resistant to exercise-induced cardiac 
hypertrophy. Furthermore, adult murine cardiac myocytes are resistant to IGF-1 
stimulated protein synthesis in vitro suggesting that Akt1 deficiency in myocytes 
account for the reduction in heart growth in this mouse model (DeBosch et al., 2006b). 
It may be useful to confirm these findings in a cardiac-specific Akt1 knockout model. 
Akt2 null mice exhibit insulin resistance and depending on genetic background, mild 
growth retardation (Cho et al., 2001a; Garofalo et al., 2003). Consistent with this, a 
mutation in the human AKT2 gene has been shown to be associated with autosomal 
dominant inheritance of severe insulin resistance and diabetes mellitus (George et al., 
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2004). Akt2 null mice displayed normal cardiac growth responses to provocative 
stimulation, including ligand stimulation of cultured cardiomyocytes, pressure 
overload by transverse aortic constriction, and myocardial infarction. However, Akt2 
is absolutely required for the maintenance of normal cardiac glucose metabolism and 
for cardiomyocyte survival in response to ischemic injury (DeBosch et al., 2006a). 
Akt3 null mice have smaller brain size due to the reduction in both cell size and cell 
number. However, they do not show the general growth retardation phenotype 
(Easton et al., 2005; Tschopp et al., 2005). Thus, data from the available Akt 
knockout models support a critical role specifically for Akt1 in normal growth of the 
heart. Akt1/Akt2 double-null animals die shortly after birth due to defects in multiple 
tissues including skeletal muscle, bone and skin (Peng et al., 2003). Akt1/Akt3 
double-mutant mice die by E12 with more severe developmental defects in the 
cardiovascular and nervous systems (Yang et al., 2005). Thus, the phenotypes of these 
compound mutants suggest functional redundancy among the three Akt proteins. 
In transgenic studies, myristoylated Akt1 (membrane-targeted Akt1, myr-Akt1) 
(Cook et al., 2002; Matsui et al., 2002; Shiojima et al., 2005) or a phosphorylation 
mimicking mutant of Akt1 (Akt1 T308D/S473D) (Shioi et al., 2002) or PH domain 
mutant of Akt1 (Akt1 E40K), which has increased affinity to phospholipids, 
(Condorelli et al., 2002; Kim et al., 2003) has been used as a constitutively active (CA) 
Akt1. One common phenotype associated with overexpression of CA-Akt1 in the 
heart is cardiac hypertrophy with an increase in myocyte size (Condorelli et al., 2002; 
Kim et al., 2003; Matsui et al., 2002; Shioi et al., 2002; Shiojima et al., 2005). And 
14 
 
the CA-Akt1 T308D/S473D mutant protein circumvented cardiac growth retardation 
induced by a KD-PI3K mutant protein (Shioi et al., 2002), suggesting Akt functions 
downstream of PI3K. In contrast, mice over-expressing kinase dead (KD)-Akt1 
(K179M), in which the critical ATP binding site was mutated, has similar heart and 
myocyte size as their control littermates. However, The KD-Akt1 mutant protein 
attenuated the CA-PI3K-induced overgrowth of the heart (Shioi et al., 2002). Cardiac-
specific myristoylated Akt3 transgenic mice also exhibited marked cardiac 
hypertrophy (Taniyama et al., 2005). 
1.4.4 Gsk3β 
Gsk3β was initially identified as a kinase that phosphorylates and inactivates 
glycogen synthase but is now recognized as a regulator of multiple processes 
including development, tumorigenesis, and metabolism (Doble and Woodgett, 2003). 
Gsk3β is constitutively active in unstimulated cells where it phosphorylates and 
negatively regulates most of its substrates. In response to RTK/GPCR activation, 
phosphorylation of the serine-9 residue in the N-terminal region of Gsk3β by Akt 
inhibits Gsk3β thereby leading to diverse effects (Doble and Woodgett, 2003; Toker 
and Cantley, 1997). Whole-body knockout of Gsk3β leads to embryonic lethality by 
E16.5 due to severe liver degeneration (Hoeflich et al., 2000). Cardiac specific 
overexpression of wildtype Gsk3β (Michael et al., 2004) or expression of Gsk3β (S9A) 
(Antos et al., 2002) reduces maturational growth of the heart, and reduces the cardiac 
hypertrophy induced by isoproterenol (ISO) infusion, transverse aortic constriction 
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(TAC) or overexpression of constitutively activated calcineurin (Antos et al., 2002), 
confirming that GSK-3β functions as a negative regulator of hypertrophy in vivo. 
Furthermore, inducible expression of Gsk3β (S9A) in the adult heart reduces the 
extent of established hypertrophy produced by TAC, as assessed by left ventricular 
weight/body weight (Sanbe et al., 2003). In contrast, cardiac overexpression of 
dominant-negative Gsk3β (K85M/K86I) results in hypertrophy (Hirotani et al., 2007).   
Several potential mechanisms are proposed for the negative regulatory role of 
Gsk3β in cardiac hypertrophy. First, Gsk3β may attenuate cardiac hypertrophy by 
phosphorylating and inducing nuclear export of NFAT (nuclear factor of activated T-
cells) (Heineke and Molkentin, 2006). Because calcineurin, a calcium-dependent 
phosphatase and a transducer of cardiac stress signals, induces of hypertrophy through 
dephosphorylation and nuclear import of NFAT (Molkentin et al., 1998), 
phosphorylation of NFAT by Gsk3β masks its nuclear localization sequence and 
antagonizes the hypertrophic effects of calcineurin. Indeed, constitutively active 
Gsk3β inhibits endothelin-1-induced NFAT nuclear import (Haq et al., 2000), and 
concomitant Gsk3β overexpression markedly reduces hypertrophy of calcineurin-
transgenic mice (Antos et al., 2002). Second, because Gsk3β induces nuclear export 
of Gata4 (Morisco et al., 2001) and reduces transcriptional activity of myocardin 
(Badorff et al., 2005), both of which are transcription factors implicated in 
hypertrophic responses of myocytes (Perrino and Rockman, 2006; Pipes et al., 2006), 
Gsk3β may attenuate cardiac hypertrophy by suppressing the activities of these 
transcription factors. Third, Gsk3β inhibits initiation of protein translation by 
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negatively regulating eukaryotic translation initiation factor 2B (eIF2B) (Dorn and 
Force, 2005) and enhanced protein synthesis is an important feature during 
hypertrophy. In cultured cardiac myocytes, it was shown that phosphorylation of 
eIF2B by Gsk3β is critical for anti-hypertrophic effects of Gsk3β (Hardt et al., 2004). 
eIF2B phosphorylation is also increased in the heart of Gsk3β transgenic mice 
(Michael et al., 2004). 
1.4.5 mTOR 
mTOR is a 289 kDa evolutionarily conserved serine/threonine kinase that is 
inhibited by the drug rapamycin (Harris and Lawrence, 2003; Schmelzle and Hall, 
2000). The best characterized function of mTOR in mammalian cells is regulation of 
translation (Inoki et al., 2005). Two most important downstream targets of mTOR are 
ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E binding protein 1 
(4EBP1), which are key regulators of protein translation (Inoki et al., 2005). 
Rapamycin has been shown to decrease agonist-induced hypertrophy in vitro 
(Sadoshima and Izumo, 1995) and load-induced hypertrophy in mice (Shioi et al., 
2003). Cardiac hypertrophy induced by Akt overexpression is effectively blocked by 
rapamycin treatment (Shioi et al., 2002; Shiojima et al., 2005).  
1.4.6 PTEN 
The role of PTEN in cardiac hypertrophy has been studied in both cultured 
myocytes and mouse models. In neonatal cardiomyocytes, expression of DN-PTEN 
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increases protein synthesis and cell size associated with elevated level of phospho-
Akt,, while overexpression of wildtype PTEN impaired these responses 
(Schwartzbauer and Robbins, 2001). Cardiac specific knockout of PTEN increases 
phospho-Akt, phospho-Gsk3β and phospho-p70S6K levels, resulting in increased 
cardiomyocyte and heart size.  And co-expression of DN-p110α  reverses the 
phenotype (Crackower et al., 2002).  
 
1.5 Overview of histone deacetylases 
Gene expression is regulated not only at the level of individual promoters, but 
also, at a more global level, by modulation of chromatin structure. Modification of 
core histones, around which DNA is wrapped, affects the packaging of nucleosomes 
and the accessibility of specific regions of DNA to transcription factors and the basal 
transcriptional machinery. Histone acetylation, mediated by HATs, results in 
chromatin relaxation and transcriptional activation (Gallinari et al., 2007), while 
HDACs induce deacetylation, chromatin condensation, and transcriptional repression 
(Ekwall, 2005; Johnson and Turner, 1999). HDACs lack intrinsic DNA binding 
ability and are recruited to target genes via their incorporation into large multiprotein 
transcriptional complexes as well as direct association with transcriptional activators 
or repressors (Grunstein, 1997). There are 11 HDACs encoded by mammalian 
genome, which can be classified into four families (class I, IIa, IIb and IV). The class 
I HDAC family consists of HDAC1, 2, 3 and 8, which are expressed ubiquitously and 
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consist mainly of a deacetylase domain with short amino- and carboxy-terminal 
extensions (Ekwall, 2005; Haberland et al., 2009). Class IIa HDACs (HDACs 4, 5, 7, 
and 9) have large N-terminal extensions in addition to the catalytic domain, and they 
have restricted express pattern. The extensions have conserved binding sites for the 
transcription factor myocyte enhancer factor 2 (MEF2) and the chaperone protein 14-
3-3 (Haberland et al., 2009). HDAC5 and HDAC9 are highly expressed in muscle, 
heart and brain (Chang et al., 2004; Zhang et al., 2002). HDAC4 is mainly found in 
the brain and growth plates of the skeleton (Vega et al., 2004), and HDAC7 is 
expressed in endothelial cells and thymocytes (Chang et al., 2006). The class IIb 
family consists of HDAC6 and HDAC10. HDAC6 mainly exists in cytoplasm in 
mammalian cells (Zhang et al., 2008). Little is known about HDAC10. HDAC11 is 
the sole class IV HDAC, which has been shown to regulate the expression of 
interleukin 10 and immune tolerance (Villagra et al., 2009).  
Mammalian HDACs are also able to deacetylate non-histone targets. 
Acetylation has been shown to affect protein stability, DNA binding, transcription 
activation, protein interactions, localization and enzymatic activity (Spange et al., 
2009). For example, acetylation of p53 activates its sequence-specific DNA binding 
activity and consequently increases activation of its target genes (Gu and Roeder, 
1997), while deacetylation of p53 by HDAC1 represses p53-dependent transcriptional 
activation and modulates p53-mediated cell growth arrest and apoptosis (Luo et al., 
2000). As p53 acetylation might favor DNA binding and transcriptional activation, 
this mechanism has likewise been suggested for the transcription factors c-Myb (Sano 
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and Ishii, 2001; Tomita et al., 2000), GATA factors (Boyes et al., 1998; Hayakawa et 
al., 2004; Yamagata et al., 2000), E2F1 (Martinez-Balbas et al., 2000; Marzio et al., 
2000), MyoD (Sartorelli et al., 1999) and many others. 
 
1.6 HDACs in regulating cardiac hypertrophy 
The roles of HDACs in cardiac hypertrophy have been investigated through 
several gene-targeting studies in the mouse. Mice lacking either HDAC5 or HDAC9 
are normal at early age. However, by about 8 months of age, mutant animals develop 
spontaneous cardiac hypertrophy that appears to reflect sensitization to age-related 
cardiac insults. HDAC5 and HDAC9 mutant mice also develop grossly enlarged 
hearts in response to pressure overload or constitutive cardiac activation of 
calcineurin (Chang et al., 2004; Zhang et al., 2002). In HDAC9 knockout animals, 
MEF2 activity is increased (Zhang et al., 2002). It is proposed that HDAC5 and 9 can 
interact with MEF2 through the N terminal extension and thus lead to repression of 
hypertrophic genes, while class I HDACs lack this domain and fail to directly regulate 
the activity of MEF2 (Lemercier et al., 2000; Lu et al., 2000a; Lu et al., 2000b; Miska 
et al., 1999; Sparrow et al., 1999; Zhang et al., 2001). Besides MEF2, class II HDACs 
have been shown to associate with and repress the transcriptional activity of SRF, 
GATA, NFAT and myocardin, each of which have been shown to regulate cardiac 
hypertrophy (Frey and Olson, 2003).  
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However, chemical HDAC inhibitors including trichostatin A (TSA), actually 
prevent cardiac hypertrophy, leading to the conclusion that distinct HDACs play 
positive or negative roles in the control of cardiomyocyte hypertrophy (Antos et al., 
2003; Kong et al., 2006). Consistent with this idea, HDAC2, a class I HDAC is 
important for inducing hypertrophy in homeodomain only protein (HOP) transgenic 
mice (Kook et al., 2003). Recently we have shown that global loss of HDAC2 results 
in partial perinatal lethality due to cardiac developmental defects that include 
enhanced cardiac myocyte proliferation. HDAC2 deficient mice were resistant to 
cardiac hypertrophy when exposed to hypertrophic stimuli (Trivedi et al., 2007). 
Resistance to hypertrophy was associated with increased expression of Inpp5f 
resulting in constitutive activation of Gsk3β via inactivation of Akt and Pdk1. While 
transgenic overexpression of HDAC2 in the heart reactivated fetal genes and induced 
cardiac hypertrophy. Inpp5f was significantly downregulated in HDAC2 transgenic 
heart (Trivedi et al., 2007). 
 
1.7 GATA4 in heart development 
In the later chapter of my thesis, I will describe some interesting HDAC2 
knockout mice phenotypes which are related to GATA4 activity. The GATA family 
of transcription factors, GATA1-6, are known to be critical for embryonic 
development, cell growth, and differentiation (Viger et al., 2008). GATA transcription 
factors are defined by an evolutionarily conserved DNA binding domain consisting of 
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two zinc finger motifs that recognize the consensus-binding site WGATAR (Ko and 
Engel, 1993; Merika and Orkin, 1993). The GATA family can be separated into two 
subgroups based on spatial and temporal expression patterns. GATA1-3 are 
predominantly expressed in hematopoietic cell lineages and are essential for erythroid 
and megakaryocyte differentiation, the proliferation of hematopoietic stem cells, and 
the development of T lymphocytes (Weiss and Orkin, 1995). In contrast, GATA4-6 
are expressed in several mesoderm and endoderm derived tissues such as the heart, 
gut and gonad (Charron and Nemer, 1999; Molkentin, 2000). GATA4 is one of the 
earliest genes expressed by specified cardiac precursors at the cardiac crescent stage 
of mouse development (Arceci et al., 1993; Kelley et al., 1993) and it has been 
extensively characterized as an essential regulator of cardiac development and 
differentiation, as well as in regulating survival and hypertrophic growth of the adult 
heart (Oka et al., 2007). GATA4 regulates the expression of genes that are important 
for cardiac contraction as well as the expression of other cardiac transcription factor 
genes, such as Mef2c, Hand2, and Nkx2-5 (Dodou et al., 2004; Lien et al., 1999; 
McFadden et al., 2000). Global loss of Gata4 in mice causes embryonic lethality at 
E9.5 as a result of severe defects in the extra-embryonic endoderm and aberrant heart 
and foregut morphogenesis (Kuo et al., 1997; Molkentin et al., 1997). Clinical studies 
have indicated a role in human congenital heart defects (CHD) (Garg et al., 2003; 
Pehlivan et al., 1999). Studies involving tissue-specific loss of Gata4 in murine 
cardiac myocytes have demonstrated a critical role for Gata4 in embryonic myocyte 
proliferation. Conditional inactivation of Gata4 using Nkx2-5 Cre resulted in 
22 
 
embryonic lethality around E11.5, with decreased cardiomyocyte proliferation and 
major defects in the development of the right ventricle (Zeisberg et al., 2005).  Mice 
lacking Gata4 in the anterior heart field (AHF), for example, die by E13.5 due to 
significant right ventricular and interventricular septal myocyte proliferation defects. 
Gata4-null cardiomyocytes show down-regulation of a wide array of cell cycle 
associated genes, some of which are direct transcriptional targets of Gata4, including 
cyclinD2 and cdk4 (Rojas et al., 2008). 
 
1.8 GATA4 post-translational modification and activity 
GATA4 activity is modulated in response to a number of intracellular signaling 
pathways, and GATA4 protein is subject to post-translational modifications including 
phosphorylation, acetylation and sumoylation (Kawamura et al., 2005; Liang et al., 
2001b; Wang et al., 2004). S105 phosphorylation by MEK1-ERK1/2 signaling 
enhances Gata4 DNA binding and transcription activation in cardiomyocytes (Kitta et 
al., 2003; Liang et al., 2001b). Gata4 is also activated by S261 phosphorylation via 
the cAMP/Protein Kinase signaling pathway in gonadal cells (Tremblay and Viger, 
2003). Sumoylation is required for Gata4 to gain the ability to activate endogenous 
cardiac-specific genes (Wang et al., 2004). The histone acetyl transferase p300 is able 
to acetylate Lys311, 318, 320, and 322 of Gata4, resulting in enhanced DNA binding 
and transcriptional activity (Takaya et al., 2008). In transgenic mice, p300 over-
expression in the heart induces Gata4 acetylation and cardiac hypertrophy (Miyamoto 
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et al., 2006; Yanazume et al., 2003a). Interestingly, p300 null mice die at E9.5 
exhibiting defects in proliferation and cardiac development (Yao et al., 1998). 
Mechanisms for Gata4 deacetylation have, to our knowledge, not been previously 
described. 
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Table 1.1: The role of phosphatases in physiology and pathology in human and 
mice 
 
Gene Function Substrate(s) Human disease Mice phenotype Reference
s 
PTEN 3-ptase PtdIns(3,4)P2
, 
PtdIns(3,4,5)
P3 
Cowden disease, 
Lhermitte-Duclos 
disease, Bannayan–
Riley–Ruvalcaba 
syndrome, Cancer 
Embryonic lethality of 
PTEN -/-. 
Tumorigenesis in 
PTEN +/-. 
(Leslie 
and 
Downes, 
2002; 
Pendaries 
et al., 
2003 
SHIP 5-ptase PtdIns(3,4,5)
P3 
Acute Myelogenous 
Leukemia 
Myeloproliferative 
phenotype with 
progressive 
splenomegaly, 
massive myeloid 
infiltration of the 
lungs, shortened 
lifespan of knockout 
mice. Severe 
osteoporotic 
phenotype. 
(Takeshita 
et al., 
2002) 
Helgason 
et al., 
1998; Liu 
et al., 
1998 
SHIP2 5-ptase PtdIns(3,4,5)
P3 
Type 2 diabetes highly resistant to 
weight gain when 
placed on a high-fat 
diet 
Grempler 
et al., 
2007; 
Sleeman 
et al., 
2005 
Synapt
ojanin 
1 
5-ptase PtdIns(4,5)P2
, 
PtdIns(3,4,5)
P3 
Bipolar disorder die shortly after birth 
due to neurological 
defects 
Cremona 
et al., 
1999; 
Saito et 
al., 2001; 
Stopkova 
et al., 
2004 
Synapt
ojanin 
2 
5-ptase PtdIns(4,5)P2
, 
PtdIns(3,4,5)
P3 
N/A N/A  
Inpp5f 5-ptase PtdIns(4,5)P2
, 
PtdIns(3,4,5)
P3 
N/A Cardiac specific KO is 
sensitive to 
hypertrophic stimuli 
Zhu et al., 
2009 
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Table 1.2: Gene-targeted and transgenic models with altered PI3K/Akt signaling 
in the heart 
Genotype Phenotype References 
Whole-body p110α KO E9.5-E10.5 lethality  Bi et al., 1999 
Cardiac-specific CA-
PI3Kα 
Increased heart and 
cardiomyocyte size 
Crackower et al., 2002; 
Shioi et al., 2000 
Cardiac specific DN-
PI3Kα 
Reduced heart and 
cardiomyocyte size 
Crackower et al., 2002; 
McMullen et al., 2003; 
Shioi et al., 2000 
Whole body PDK1 KO E9.5 lethality Lawlor et al., 2002 
Cardiac-specific PDK1 Cardiomyopathy, reduced 
cardiomyocyte size, 
increased sensitivity to 
hypoxia, increased 
cardiomyocyte apoptosis 
Ito et al., 2009; Mora et 
al., 2003 
Whole body Akt1 KO Growth retardation, 
normal glucose tolerance, 
defective in physiological 
hypertrophy 
Chen et al., 2001; Cho et 
al., 2001b; DeBosch et al., 
2006 
Whole body Akt2 KO Insulin resistance, mild 
growth retardation, normal 
cardiac growth 
Cho et al., 2001a; Garofalo 
et al., 2003; DeBosch et 
al., 2006a 
Whole body Akt3 KO Reduced brain size Easton et al., 2005; 
Tschopp et al., 2005 
Cardiac-specific CA-Akt1 
(myr-Akt1) 
Cardiac hypertrophy, 
normal myocardial 
contractility 
Matsui et al., 2002; 
Shiojima et al., 2005 
Cardiac-specific CA-Akt1 
(Akt1 T308D/S473D) 
Cardiac hypertrophy, 
reduced myocardial 
contractility 
Shioi et al., 2002 
Cardiac-specific CA-Akt1 
(Akt1 E40K) 
Cardiac hypertrophy, 
enhanced myocardial 
contractility 
Condorelli et al., 2002; 
Kim et al., 2003 
Cardiac-specific KD-Akt1 
(Akt1 K179M) 
attenuated the CA-PI3K-
induced overgrowth of the 
heart, normal myocardial 
contractility 
Shioi et al., 2002 
Cardiac-specific CA-Akt3 
(myr-Akt1) 
Cardiac hypertrophy, 
reduced myocardial 
contractility 
Taniyama et al., 2005 
Whole body Gsk3β KO E16.5 lethality Hoeflich et al., 2000 
Cardiac-specific Gsk3β Reduced maturational 
growth of the heart 
Michael et al., 2004 
Cardiac-specific CA 
Gsk3β (Gsk3β S9A) 
Impaired hypertrophic 
responses 
Antos et al., 2002 
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Cardiac-specific inducible 
Gsk3β (Gsk3β S9A) 
Reversal of pre-existing 
hypertrohpy 
Sanbe et al., 2003 
Cardiac-specific DN 
Gsk3β (K85M/K86I) 
Cardiac hypertrophy with 
improved contractility 
Hirotani et al., 2007 
Whole body knockin of 
Gsk3β (Gsk3β S9A) 
Reduced hypertrophy Matsuda et al., 2008 
Cardiac-specific CA-
mTOR 
Normal response to 
hypertrophic stimuli 
Shen et al., 2008 
Cardiac-specific KD-
mTOR 
Normal response to 
hypertrophic stimuli, 
reduced function 
Shen et al., 2008 
Muscle-specific PTEN KO Increased heart and 
cardiomyocyte size; 
reduced myocardial 
contractility 
Crackower et al., 2002, 
Oudit et al., 2008 
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Figure 1.1: Overview of the PI3K/Akt pathway. 
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Figure 1.1: Overview of the PI3K/Akt pathway. 
Upon activation, PI3K translocates to the cell membrane, converting PIP2 to PIP3. 
The PH domain of both Akt and its activator PDK1 associate with PIP3 allowing 
PDK1 to activate Akt. Activation of Akt then leads to activation of mTOR, a central 
regulator of protein synthesis. Akt also phosphorylates and inhibits a kinase, Gsk3β. 
Since Gsk3β inhibits protein translation and a number of transcription factors believed 
to play roles in the induction of the hypertrophic program of gene expression, 
inhibition of Gsk3β promotes both protein synthesis and gene transcription. 
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Chapter 2 Inpp5f is a Polyphosphoinositide Phosphatase that 
Regulates Cardiac Hypertrophic Responsiveness 
 
Significant portions of this chapter have been published in Circulation Research (Zhu 
et al., 2009).  
 
2.1 Summary 
Cardiac hypertrophy occurs in response to a variety of extrinsic and intrinsic 
stimuli that impose increased biomechanical stress. The PI3K/Akt pathway has 
previously been strongly associated with hypertrophic signaling in the heart, and with 
the control of cell size in multiple contexts. This pathway is tightly regulated by many 
factors, including a host of kinases and phosphatases that function at multiple steps in 
the signaling cascade. For example, the PTEN tumor suppressor protein is a 
phosphoinositide 3-phosphatase that, by metabolizing PtdIns(3,4,5)P3, acts in direct 
antagonism to growth factor stimulated PI3K. Inhibition of PTEN leads to 
cardiomyocyte hypertrophy.  Here, I characterize another polyphoinositide 
phosphatase, inositol polyphosphate-5-phosphatase F (Inpp5f), which has recently 
been implicated in regulation of cardiac hypertrophy. Like PTEN, this phosphatase 
can degrade PtdIns(3,4,5)P3 and thus modulates the PI3K/Akt pathway. Inpp5f 
knockout mice have augmented hypertrophy and reactivation of the fetal gene 
program in response to stress when compared to wild type littermates.  Furthermore, 
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cardiac over-expression of Inpp5f in transgenic mice reduces hypertrophic 
responsiveness.  These results suggest that Inpp5f is a functionally important 
endogenous modulator of cardiac myocyte size and of the cardiac response to stress. 
 
2.2 Introduction 
Cardiovascular disease remains the number one cause of mortality in the 
Western world, with heart failure representing the fastest growing subclass over the 
past decade (Heineke and Molkentin, 2006).  In many cases, cardiac hypertrophy 
precedes cardiac dilation and heart failure. Cardiac hypertrophy can occur in response 
to normal physiological stimuli or may be maladaptive leading to cardiac dilatation 
and congestive heart failure. However, the cellular mechanisms that regulate the 
hypertrophic response to agonists or to stretch remain poorly understood, and the 
transition from hypertrophy to failure is also ill-defined. On the other hand, evidence 
accumulating over the last few decades confirms that intercellular signaling pathways 
and gene expression are fundamentally altered in states of hypertrophy and failure and 
a thorough understanding of these changes will provide therapeutic targets (Dorn and 
Force, 2005).  
Recently, we showed that Hdac2 deficient mice are resistant to cardiac 
hypertrophy when exposed to hypertrophic stimuli (Trivedi et al., 2007). Resistance to 
hypertrophy in Hdac2-/- mice is associated with increased expression of the gene 
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encoding inositol polyphosphate-5-phosphatase f (Inpp5f) and constitutive activation 
of Gsk3β via inactivation of Akt and Pdk1. Conversely, transgenic over-expression of 
Hdac2 in the heart reactivates fetal genes and induces cardiac hypertrophy. In these 
transgenic hearts, Inpp5f is significantly down-regulated, Akt is activated, and Gsk3ß 
is inactive (Trivedi et al., 2007).  Further studies suggest that Hdac2 is a direct 
regulator of Inpp5f (Trivedi et al., 2007).  Thus, I hypothesized that Inpp5f might 
functionally contribute to cardiac regulation of the Akt/Gsk3β pathway in response to 
stress. 
Inpp5f is one of several polyphosphoinositide phosphatases that have been 
identified and partially characterized (Astle et al., 2007). Prior work demonstrates that 
Inpp5f can degrade both phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2, PIP2) 
and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3, PIP3) by removing the 
5’ phosphate from the inositol ring(Minagawa et al., 2001). Although the PIP3 3’ 
phosphatase PTEN has previously been shown to regulate cardiac myocyte 
hypertrophy and Akt signaling in the heart (Crackower et al., 2002; Oudit et al., 2004), 
a functional role for a PIP3 5’ phosphatase in the heart has been less clear.  However, 
in various non-cardiac model systems, both 3’ and 5’ inositol phosphatases are 
important regulators of PIP3 activity and downstream signaling.  For example, the 
SH2 domain-containing inositol 5'-phosphatase (SHIP) and PTEN both play 
important roles to regulate PIP3 and Akt in immune cells (Kashiwada et al., 2007). 
In order to determine the role of Inpp5f in the adult heart, I have created both 
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gain- and loss-of-function models. Our results indicate that Inpp5f transgenic mice are 
unable to reactivate fetal genes or to exhibit normal hypertrophic responses to 
adrenergic agonists, while Inpp5f knockout mice exhibit augmented hypertrophy and 
exaggerated reactivation of the fetal gene program under stress.  
 
2.3 Results 
2.3.1 Inpp5f regulates the PI3K/Akt pathway in vitro 
Inpp5f removes the 5-phosphate from PIP3 (Minagawa et al., 2001) and thus I 
predicted that Inpp5f is able to affect PI3K/Akt pathway activity. To test this, I 
performed both transfection overexpression and siRNA knockdown experiments in 
H9C2 cells, a cardiomyocyte cell line. Transfection of Inpp5f resulted in down-
regulation of pAkt and pGsk3β (Fig 2.1A). This effect was readily apparent despite an 
estimated transfection efficiency of 50%. The decrease in Akt and Gsk3β 
phosphorylation induced by Inpp5f overepression was reversed by co-transfection 
with a constitutively activated Akt (caAkt) (Fig 2.1A), suggesting that Akt is 
downstream of Inpp5f and is capable of regulating Gsk3β. Knockdown of Inpp5f in 
H9C2 cells with siRNA resulted in enhanced Akt phosphorylation (Fig 2.1B). Thus, 
Inpp5f is capable of modulating the Akt-Gsk3β pathway in vitro. 
 
33 
 
2.3.2 Generation of Inpp5f antibody 
To our knowledge, there are no commercially available Inpp5f antibodies. In 
order to facilitate the study, I chose two epitope antigens (one from N-terminus and 
the other from C-terminus of the protein) for antibody generation based on 
hydrophilicity, orientation, flexibility and antigenecity analysis. I cloned these two 
regions into pGEX-2T vectors separately. The plasmids were transformed into BL21 
bacteria and glutathione S-transferase (GST) fusion proteins were extracted, purified 
and confirmed by Coomassie blue staining (Fig 2.2A). The fusion proteins were then 
sent to Cocalico Biologicals, Inc (Reamstown, PA) for injection into rabbit. By 
computer prediction, the mouse Inpp5f protein is 129 kD. To confirm this prediction, I 
made an N-terminal FLAG-tagged Inpp5f and a C-terminal MYC-tagged Inpp5f, 
transfected into Cos7 cells and probed the cell proteins with either anti-FLAG 
antibody or the anti-MYC antibody (Fig 2.2B). A predominant 130 kD band is 
observed in Fig 2.2B. The rabbit anti-sera after the second injection was examined on 
both FLAG-tagged Inpp5f containing vector and empty vector transfected cells. The 
result shows that all four antibodies could recognize a band approximately 130 kD in 
the Inpp5f expressing cells which was not detected in the control transfected cells (Fig 
2.2C). Therefore, all 4 antibodies could recognize a protein of the predicted molecular 
weight. Since the antibody #2086 gives less background, it was chosen for future 
studies. 
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2.3.3 Inactivation of Inpp5f 
In order to produce mice lacking Inpp5f, we identified a gene-trap embryonic 
stem (ES) cell line in which the endogenous Inpp5f locus has been disrupted within 
intron 6, upstream of the exons encoding the catalytic phosphatase domain.  This 
gene-trap insertion is predicted to result in the production of a fusion protein 
composed of the amino-terminal region of Inpp5f fused to ß-geo (Fig 2.3A). 
Heterozygous gene-trap ES cells were injected into blastocysts to create chimeric 
mice, which were bred to produce germ-line offspring.  Resulting heterozygous mice 
were inter-crossed to produce homozygous Inpp5f-/- offspring, which were born in 
expected Mendelian ratios (Table 2.1), survived into adulthood and appeared healthy.  
Genotype was confirmed by Southern blot (Fig 2.3B) and by PCR (Fig 2.3C). I 
confirmed the lack of full length Inpp5f transcripts by real-time PCR using mRNA 
from adult Inpp5f-/- and wild-type hearts (Fig 2.3D). Western blot using antibody 
recognizing the C-terminus of Inpp5f demonstrated a lack of protein expression in the 
knockout (Fig 2.3E). Thus, I conclude that I have generated a null allele for Inpp5f.   
 
2.3.4 Further characterization of the Inpp5f genomic locus 
Since the insertion is predicted to result in a fusion protein with the N-terminal 
region of Inpp5f fused to β-geo, I sought to detect the β-gal activity in the knockouts. 
I performed β-gal staining in E13.5 embryos as well as in several tissues of adult mice 
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including the brain, liver and heart. However, I did not detect any β-gal staining (data 
not shown). To exclude the possibility that the level of expression is too low to detect, 
I utilized a sensitive β-galactosidase assay (Shaper et al., 1994; Young et al., 1993).In 
the protein extracts from the Z/EG reporter mouse tail, which constitutively express 
lacZ under the control of the CMV promoter (Novak et al., 2000), I was able to detect 
large amounts of β-galactosidase activity. However, analysis of tissues from knockout 
mice yielded results similar to those of the wildtypes (data not shown) and they are far 
below the positive control.  
I sought to further analyze the Inpp5f genomic locus to make sure that the β-
geo cassette is inserted in the right locus and the mice are true knockouts. First of all, 
I designed several primers to map the exact locus where the cassette is inserted (Fig 
2.4A). As seen in Fig 2.4B, the cassette is somewhere between primer R3 and R4 
within intron 6.  I cloned the PCR product from FR3 in Fig 2.4A and sequencing 
suggests that the insertion is at the 1752nd nucleotide within intron 6, which has 3291 
nucleotides total. PCR from cDNA from the heart shows the existence of the fusion 
transcript of the first 6 exons and β-geo (Fig 2.4C, D). Further in depth analysis of the 
Inpp5f genomic locus affected by the gene-trap revealed that the insertion event was 
accompanied by a loss of endogenous genomic sequence spanning exons 7-13 (Fig 
2.5).  Thus, the affected allele cannot produce a full-length protein or one with 
functional phosphatase activity.  There are several possibilities why the fusion 
transcript is produced but no β-galactosidase activity is detected. Perhaps the fusion 
protein is not stable. It is also possible that large deletion of gemonic DNA results in a 
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loss of some important enhancer elements that are required for efficient tissue-specific 
transcription. 
 
2.3.5 Inpp5f null hearts appear normal 
We examined cardiac histology, size and function in Inpp5f-/- and littermate 
control mice. H&E staining of hearts was performed at E14.5, P0 and 2 months of age. 
At these time points, we could not identify any differences and Inpp5f null mice 
appear normal by gross and histological assessment (Fig 2.6A). We measured cardiac 
weight in relation to total body weight to determine relative cardiac size.  At both 2 
and 9 months of age, there was no difference in heart to body weight ratio between 
wild type and Inpp5f-/- littermates (Fig 2.6B, C). 
In order to evaluate the functional impact of the loss of Inpp5f, we performed 
echocardiography on Inpp5f-/- and wild type litter mates at 2 and 9 months (Table 2.2). 
We did not observe any significant difference in the inter-ventricular septum (IVS), 
left ventricular posterior wall (LVPW) and the left ventricular internal diameter (IVID) 
measurements at either end-diastole or end-systole. Left ventricular (LV) ejection 
fraction (EF) and fractional shortening (FS) also was not different between groups. 
Thus, under basal conditions, Inpp5f-/- mice appear to have normal cardiac form and 
function. 
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2.3.6 Inpp5f regulates stress-induced hypertrophy 
Next, we sought to determine if adult mice lacking Inpp5f would be more 
susceptible to agonist-induced cardiac hypertrophy. Wild-type and Inpp5f-/- litter 
mates at 2 months of age were treated with a constant infusion of saline or 
isoproterenol (ISO) delivered by osmotic mini-pump for 14 days. Animals lacking 
Inpp5f showed an increase in ISO-induced cardiac hypertrophy as measured by either 
the heart to body weight ratio or the heart weight to tibia length ratio (Fig 2.7A). In 
response to ISO, Inpp5f-/- heart also showed more potent reactivation of the fetal 
program of gene expression than wild type litter mates; transcripts for Nppa (encoding 
atrial natriuretic factor, ANF), Myh7 (encoding β-MHC) and Nppb (encoding BNP) 
increased more dramatically in the knockout hearts (Fig 2.7B). Cellular hypertrophy, 
as revealed by wheat germ agglutinin (WGA) staining followed by quantification, was 
more pronounced in the Inpp5f-/- hearts compared to wild-type hearts after ISO (Fig 
2.7C) (256.5 + 21.8 µm2 for Inpp5f -/- mice treated with ISO, n = 446 cells from 3 
hearts; 194.8 + 6.8 µm2 for wild type mice treated with ISO, n = 514 from 3 hearts). 
Patchy areas of fibrosis were more evident in ISO-treated Inpp5f-/- hearts when 
compared to controls (Fig 2.7D) (Quantification of fibrotic area was 7.3% for Inpp5f -
/-
 mice, 25 sections, three hearts; 1.8% for wild type mice, 27 sections, three hearts). 
We also observed more apoptotic cells in the Inpp5f-/- hearts after ISO treatment 
compared to wild type (0.37% of 16,804 cells from 4 Inpp5f-/- hearts, 0.24% of 21,558 
cells from 5 wild type hearts, p = 0.01). Functional assessment by echocardiography 
after 2 weeks of ISO treatment revealed relative preservation fractional shortening 
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and ejection fraction, with thickening of the posterior wall in Inpp5f-/- animals at this 
time point (Table 2.3). 
Neonatal myocytes isolated from Inpp5f-/- and wild type littermates revealed 
similar levels of Akt and Gsk3ß phosphorylation under basal conditions (Fig 2.7E).  
Treatment with ISO resulted in increased phosphorylation of Akt and Gsk3β in 
knockout cells when compared to controls (Fig. 2.7E), while no significant 
differences in Erk activation were noted (data not shown). IGF-1 treatment of 
myocytes revealed similar results (data not shown). Taken together, our data suggest 
that cardiac myocytes lacking Inpp5f are sensitive to stress-induced cardiac 
hypertrophy and activation of the Akt pathway. 
 
2.3.7 PIP3 levels are altered in Inpp5f null mice 
Although a prior report has indicated that Inpp5f exhibits 5-phosphatase activity 
when PtdIns(3,4,5)P3 and PtdIns(4,5)P2 are used as substrates in vitro (Minagawa et 
al., 2001), I sought to determine directly if loss of Inpp5f alters endogenous cardiac 
PIP3 levels in vivo. Endogenous PtdIns(3,4,5)P3 levels are low, and I am unaware of 
prior studies that directly measure levels of this important signaling molecule in vivo 
in genetically engineered animals.  Therefore, I took two approaches simultaneously. 
First, I pursued collaboration with Dr Andrew Quong at the Thomas Jefferson 
University to measure the PIP3/PIP2 levels in the lipid extraction from adult knockout, 
39 
 
Tg and wildtype hearts by mass spectrometry. Our preliminary results (Fig 2.8A) with 
wild type hearts suggest that accurate measurements would be possible though 
significant optimization is required. The major problem is that signals are weak and 
they don’t separate well enough from other signals. All the major signals turned out to 
be glycerophosphocholine, sphingomyelin, glycerophosphoethanolamide and 
glycerophosphatidic acids. As an alternative approach, I adapted an ELISA-based 
sensitive assay that has been used for cultured cells and compared PIP3 levels in 
control and Inpp5f-/- hearts before and after ligand stimulation intended to augment 
PIP3 levels. Heart tissue from 4 mice age 3-5 weeks was combined for each condition, 
and some samples were treated ex vivo with IGF-1, a potent activator of PI3K and 
AKT in the heart.  Our data shows that PIP3 levels in Inpp5f-/- mice are ~1.6 fold 
greater than wild type littermates. However, upon IGF-1 stimulation, PIP3 levels in 
the knockout hearts increased to 4.9 fold those of stimulated wild type littermates (Fig 
2.8B). Thus, loss of Inpp5f sensitizes the heart to hypertrophic stimulation.  
 
2.3.8 Cardiac-specific Inpp5f transgenic mice  
I used the well-characterized α-myosin heavy chain (α-MHC) promoter to 
direct cardiac-restricted expression of Inpp5f in transgenic mice (Fig 2.9A).  I utilized 
two distinct strategies.  First, I generated Flag-tagged Inpp5f.  However, epitope 
tagging always has the possibility of affecting protein function. Therefore, I also 
generated a transgenic construct in which I included an IRES-GFP sequence after the 
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Inpp5f coding region.  With this construct, I would be able to easily determine if the 
transgene is specifically expressed in the heart (via GFP expression) and accurate 
transgenic protein levels would be determined by the Inpp5f antibody I generated. 2 
transgenic lines were generated for the Flag-tagged transgenic mice and 6 lines were 
generated for the IRES-GFP transgenic mice in order to control for effects mediated 
by sites of insertion. With both two strategies, I was able to confirm the germline 
transmission of the transgene by PCR (Fig 2.9B).  For the Flag-tagged Inpp5f 
construct, I was also able to determine the transgene mRNA level by real-time PCR 
(data not shown) and verify the transgenic expression by Western blotting (Fig 2.9C) 
which revealed similar levels of protein expression in the two independent lines. 
However, for the IRES-GFP construct, Real-time PCR for Inpp5f gene didn’t show 
any increase in the mRNA level (data not shown) and Western Blot for GFP didn’t 
show detectable expression either (Fig 2.9D), which may be due to gene silencing, 
recombination, etc. I analyzed the phenotypes using the two lines of Flag-Inpp5f 
transgenic mice. 
 
2.3.9 Inpp5f transgenic mice are resistant to stress-induced hypertrophy 
Adult Inpp5f transgenic mice appeared healthy. Heart to body weight ratios of 
transgenic and wild type littermates were not significantly different at P60 (Fig 
2.10A).  Control and Inpp5f transgenic littermates at 2 months of age were treated 
with a constant infusion of saline or ISO for 14 days. As predicted, wild-type mice 
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exhibited cardiac hypertrophy, as revealed by an increase in both the heart to body 
weight ratio and the heart weight to tibia length ratio (Fig 2.10A). Hypertrophy of 
Inpp5f transgenic mice in response to ISO was significantly blunted (Fig 2.10A).  
Likewise, reactivation of the fetal gene program that accompanied hypertrophy in 
control animals was markedly attenuated in transgenic animals (Fig 2.10B). After 
treatment with ISO, we noted activation of the Akt pathway with enhanced 
phosphorylation of Akt and Gsk3ß in the control hearts (Fig 2.10C).  However, ISO-
induced increases in phospho-Akt and phospho-Gsk3ß were blunted in transgenic 
hearts.   
 
2.3.10 Inpp5f has a Sac domain and it has the conserved catalytic motifs 
As discussed in the introduction, Inpp5f has a Sac domain, which is 
approximately 400 amino acid residue in length and defined by seven conserved 
motifs which appear to define the catalytic and regulatory regions of the 
phosphatase(Hughes et al., 2000). The highly conserved sequence 
RXNCXDCLDRTN in the sixth motif is proposed to be the catalytic core of the SAC 
domain phosphatases. The SAC domain of the yeast synaptojanin-like protein Inp51p 
does not exhibit phosphatase activity, and the cysteine, arginine and threonine/serine 
residue are absent from CX5R(T/S) motif of this protein. In order to examine whether 
this novel protein also has these seven conserved motifs and the active catalytic core, 
I downloaded the sac1p and the Inp51p protein sequences in S.cerevisiea from NCBI, 
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and aligned these sequences together with the human and mouse Inpp5f sequences by 
CLUSTALW(Chenna et al., 2003). Sac1p exhibits phosphatase activity and actually it 
is the first protein in which the Sac domain is identified(Guo et al., 1999; Hughes et 
al., 2000). I identified seven highly conserved motifs and the sixth conserved region 
of Inpp5f in both mouse and human has the highly conserved CX5R(T/S) motif (Fig 
2.11). 
 
2.3.11 Interaction of Inpp5f with PDK1 
I have showed that one mechanism for Inpp5f to regulate PI3K/Akt pathway is 
by dephosphorylating PIP3. As an attempt to look for other mechanisms how Inpp5f 
might affect this pathway, I identified a potential PDK1 interaction domain. I 
hypothesized that Inpp5f would interact with PDK1 and down-regulate its activity. I 
tested the interaction by co-transfecting Flag tagged Inpp5f and Myc tagged PDK1 
and performing co-immunoprecipitation. As shown in Fig 2.12, I didn’t detect any 
interaction between Inpp5f and PDK1. Some possibilities exist. First, PDK1 might 
interact with Inpp5f only under certain conditions, such as activation of the PI3K/Akt 
pathway. Second, some post-translational modifications might be required for the 
interaction, such as phosphorylation, acetylation, etc. Further experiment could be 
performed to detect the interaction under other conditions. 
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2.3.12 Genetic epistasis analysis 
We have demonstrated that Hdac2 promotes cardiac hypertrophy and Inpp5f is 
up-regulated in Hdac2 knockout hearts, both during late gestation and in the adult 
while it is down-regulated in Hdac2 transgenic mice that over-express Hdac2 in the 
heart. Hdac2 can deacetylate histones at the Inpp5f upstream genomic region, 
consistent with direct regulation (Trivedi et al., 2007). My data also suggests that 
Inpp5f transgenic mice were unable to reactivate fetal genes or to exhibit normal 
hypertrophic responses and the transgenic hearts have decreased levels of phospho-
AKT and phospho-GSK3β. In contrast, Inpp5f knockout mice have augmented 
hypertrophy associated with reactivation of the fetal gene program. However, it 
remains unclear to what extent Hdac2 regulates hypertrophy via Inpp5f as opposed to 
other, yet to be identified, mechanisms. To examine this, I crossed Hdac2+/- mice to 
Inpp5f-/- mice, and the resulting Hdac2+/-, Inpp5f+/- offspring were intercrossed to 
produce Hdac2-/-, Inpp5f-/- animals. I expect that the absence of Inpp5f will restore 
hypertrophic responsiveness in Hdac2 knockout mice. Table 2.4 shows the genotyping 
result I have obtained so far. I have not detected any double nulls, which could be 
either due to limited numbers or embryonic lethality. More genotyping and further 
analysis are needed to investigate this question. 
Similarly, my work has also supported a role of Akt in the phenotypes I 
observed in Inpp5f knockout and transgenic mice. Deletion of Inpp5f leads to higher 
level of phospho-Akt and reactivation of fetal gene programs, which results in 
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sensitivity to hypertrophic stimuli. To further test the genetic epstasis of this pathway, 
I crossed Akt+/- mice, a general gift from Dr. Morris J. Birnbaum, to Inpp5f-/- mice, 
and then I crossed the resulting Akt+/-, Inpp5f+/- offspring to produce Akt-/-, Inpp5f-
/- animals. Table 2.5 displays the genotyping result. Likewise, more numbers are 
necessary before firm conclusions can be made. 
 
2.4 Discussion 
In this study, we investigated the effects of gain- and loss-of-function of Inpp5f. 
Our results suggest that Inpp5f modulates stress-induced hypertrophic responsiveness 
in the heart. Under basal conditions, Inpp5f knockout and transgenic mice appear 
normal, with preserved cardiac structure and function.  However, in the setting of 
adrenergic stimulation produced by infusion of isoproterenol, Inpp5f-/- animals had 
elevated level of PIP3 and showed accentuated hypertrophy as measured by heart size, 
myocyte size and gene expression.  Isolated myocytes lacking Inpp5f were 
hypersensitive to ISO and IGF-1 as reflected by accentuated activation of Akt 
compared to control myocytes.  Conversely, Inpp5f transgenic mice were relatively 
resistant to hypertrophic stimulation. 
Inpp5f encodes a 5’ PIP3 phosphatase that is predicted to reduce PIP3 levels 
and subsequent activation of Akt and downstream signals.  Our biochemical findings 
in Inpp5f transgenic and knockout hearts are consistent with this mode of action.  The 
45 
 
Akt signaling network in the adult heart has been extensively examined and has been 
shown to contribute to both adaptive (physiologic) and maladaptive (pathologic) 
hypertrophy(Oudit et al., 2004). Akt1-/- mice have a 20% reduction in body size, with 
a concomitant reduction in heart size(Cho et al., 2001b) and they are defective in 
exercise-induced cardiac hypertrophy(DeBosch et al., 2006b). Cardiac specific over-
expression of constitutively active or dominant negative forms of Akt lead to larger or 
smaller hearts respectively(Condorelli et al., 2002; Matsui et al., 2002; Shioi et al., 
2002). Enhanced Akt activity is associated with increased p70S6 kinase activity and 
increased phospho-Gsk3β(Matsui et al., 2002; Shioi et al., 2002). Cardiac-specific 
over-expression of constitutively active Gsk3β is associated with reduced agonist and 
pressure-overload hypertrophy confirming that Gsk3β functions as a negative 
regulator of hypertrophy in vivo(Zhang et al., 2002). Thus, the alterations in Akt and 
Gsk3β phosphorylation that we observed in Inpp5f knockout and transgenic hearts are 
consistent with a model in which Inpp5f regulates PIP3 levels, Akt and Gsk3β activity 
and subsequent hypertrophic responsiveness.  
The inositol polyphosphate 5-phosphatases are a large family of enzymes 
comprising at least 10 mammalian and 4 yeast members(Astle et al., 2006).  Inpp5f 
has a Sac phosphatase domain which exhibits phosphatidylinositol polyphosphate 
phosphatase activity(Minagawa et al., 2001). The Sac domain is approximately 400 
amino acid residue in length and defined by seven conserved motifs which appear to 
define the catalytic and regulatory regions of the phosphatase(Hughes et al., 2000). 
The highly conserved sequence RXNCXDCLDRTN in the sixth motif is proposed to 
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be the catalytic core of the SAC domain phosphatases. The CX5R(T/S) motif within 
this sequence is also found in a number of metal-independent protein phosphatases 
and inositol polyphosphate phosphatases and is known to be a phosphatase catalytic 
site(Guo et al., 1999; Hughes et al., 2000). Interestingly, the SAC domain of the yeast 
synaptojanin-like protein Inp51p does not exhibit phosphatase activity, and the 
cysteine, arginine and threonine/serine residue are absent from CX5R(T/S) motif of 
this protein, being replaced by alanine, lysine and proline respectively. Furthermore, 
mutations of the first conserved aspartate residue in the RXNCXDCLDRTN sequence 
as seen in the yeast sac1-8 and sac1-22 mutant alleles were demonstrated to inactivate 
the Sac1p functions(Hughes et al., 2000; Kearns et al., 1997; Zhong and Ye, 2003).  
Some 5-phosphatases, such as the Src homology 2 (SH2) domain-containing 
inositol polyphosphophate 5-phosphatases 1 and 2 (Ship and Ship2) have been 
extensively characterized(Backers et al., 2003; Dyson et al., 2005; Harris et al., 2008; 
Krystal et al., 1999; Rohrschneider et al., 2000). Ship is expressed predominantly in 
hematopoietic cells where it is an important negative regulator of cytokine signaling. 
Ship-/- mice have a short life span associated with massive myeloid cell infiltration of 
the lungs and numerous hematopoietic abnormalities(Helgason et al., 1998; Liu et al., 
1998). Ship2 is more widely expressed, with high expression in brain, skeletal muscle 
and heart(Astle et al., 2006). It plays an important role in insulin signaling and obesity 
regulation(Grempler et al., 2007; Sleeman et al., 2005).  Ship2 has been reported to be 
a negative regulator of Akt activation. Although loss of Ship2 is not sufficient to 
activate Akt, the absence of Ship2 allows for greater activity upon Akt 
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stimulation(Rommel et al., 2001; Wada et al., 2001). These findings are reminiscent 
of our results with regard to Inpp5f-mediated regulation of basal and agonist-induced 
activation of Akt in the heart. 
Although PTEN and the 5-phosphatases can all degrade PIP3, the degradation 
products are distinct. Whereas PTEN converts PIP3 to PI(4,5)P2, the 5-phosphatases 
convert PIP3 to PI(3,4)P2, which can function as a second messenger (Dowler et al., 
2000). Therefore, the production of PI(3,4)P2 from PIP3 by Inpp5f and Ship 
phosphatases may function in part via active signaling, whereas PTEN action appears 
to be mediated through loss of active PIP3 signaling(Leslie and Downes, 2002). For 
example, PI(3,4)P2 has been shown to activate reactive oxygen species (ROS)(Brown 
et al., 2003) and the generation of ROS is a process that is increasingly recognized as 
an important contributor to depressed cardiac function and maladaptive 
remodelling(Takimoto and Kass, 2007). Thus, this process could also contribute to the 
phenotype we observed. Moreover, PI(3,4)P2 activity has been shown to correlate 
with Akt phosphorylation and activity(Ma et al., 2008). Inpp5f can also 
dephosphorylate PI(4,5)P2(Minagawa et al., 2001), and depletion of PI(4,5)P2 may 
contribute to cardiomyocyte apoptosis and subsequent heart failure(Halstead et al., 
2005). Thus, regulation of PI(4,5)P2 levels may contribute to the mechanism by 
which Inpp5f regulates hypertrophy. 
Under the sedentary conditions, we found that Inpp5f null mice have slightly 
higher level of cardiac PIP3, though phospho-Akt and phospho-Gsk3β are unaltered 
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and the mice do not show abnormal hypertrophy. However, upon IGF-1 stimulation, 
PIP3 levels in the knockout mice increase dramatically and they are more sensitive to 
hypertrophic stimuli. Hence, unlike PTEN, which alters the basal level of PIP3(Leslie 
and Downes, 2002), Inpp5f appears to modulate PIP3 levels primarily upon agonist-
induced stimulation.  
Our prior studies have suggested that Inpp5f is repressed at the transcriptional 
level by Hdac2.  Inpp5f transcripts are elevated in Hdac2 knockout hearts and are 
diminished by over-expression of Hdac2 in the heart.  siRNA-mediated knockdown of 
Hdac2 or chemical Hdac inhibition in H9C2 myocytes results in increased levels of 
Inpp5f and decreased phosphorylation of Akt and Gsk3ß.  Although Hdac2 may 
modulate cardiac myocyte size and hypertrophic signaling via multiple pathways, our 
analysis of Inpp5f knockout and transgenic mice are consistent with a functional 
relationship between Hdac2 and Inpp5f in the setting of hypertrophic stimulation.  
Taken together, the work presented here suggests that Inpp5f functions as a 
negative regulator of cardiac hypertrophy and Akt signaling.  Loss of Inpp5f sensitize 
the heart’s response to hypertrophic stimuli by modulating PI(3,4,5)P3 levels. 
 
2.5 Materials and methods 
Inpp5f-/- knockout mice. An Inpp5f gene-trap ES clone was obtained from 
BayGenomics (now the International Gene Trap Consortium, ES clone no. XL0571). 
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The Inpp5f genomic locus is interrupted by insertion of the pGT01xf vector, which 
integrated into intron 6. Chimeric mice were produced by blastocyst injection 
according to standard protocols. Mice were genotyped by Southern blotting analysis 
of ScaI digested genomic DNA. Inpp5f+/+ and Inpp5f–/– mice were subsequently 
genotyped by PCR using:  
Wt F: 5' -AAAGCAGGTTGTGAAGTGGAGCTG- 3',  
Wt R: 5' -TGCTCTTGTCATCATCCGAGGACT- 3',  
Mut F: 5' -ATATTGAAACCCACGGCATGGTGC- 3' and  
Mut R: 5' -TTTGATGGACCATTTCGGCACAGC- 3' primers. The mutant mice have 
one band at 323 bp, and the wild type mice have one band at 1039 bp. 
The loss of Inpp5f was confirmed by qRT-PCR using  
5' -ACAGGAGAAAGGAAGTTGGCAGGA -3' and  
5' -AGCTTCATGCTCCTTCTCCTTGGT -3' primers, and by Western blot analysis 
using a rabbit polyclonal antibody targeted to the C terminus of Inpp5f (generated by 
our lab, see below). 
 
Inpp5f-transgenic mice. A cDNA encoding human Flag-tagged Inpp5f was cloned 
into an expression plasmid containing the Myh6 (encoding α-Mhc) promoter(Heine et 
al., 2005), and transgenic mice were generated by standard techniques. Genotyping 
was performed by PCR analysis of genomic DNA using 5'-
TCTTCCAAGCCAAGGACCACTACA- 3' and 5' - 
TCTGCACGGAATTGGTCAGGTCAT- 3', and cardiac specific expression of Inpp5f 
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was revealed by qRT-PCR using 5' -ACAGGAGAAAGGAAGTTAGCAGGA- 3' and 
5' -AGCTTCATGTTCTTTCTCCTTGGT- 3' primers and Western blot analysis using 
antibodies to Flag (Sigma, F3165) or Inpp5f (generated by our lab, see below). 
 
Inpp5f antibody generation. GST-Inpp5f fusion protein was expressed in bacteria, 
purified by standard techniques and used to immunize rabbits (Cocalico Biologicals 
Inc). A region of mouse Inpp5f cDNA encoding 61 C-terminal amino acids was 
amplified by PCR using primers 5'-CGGACTGGCTTCACAAAGCCCA-3', 5'-
AGGAGGCGTCTGTCCCATTGGT-3' and cloned into the pGEX-2T vector. The 
GST fusion protein was expressed in BL21 bacteria, extracted and purified using 
Glutathione Sepharose 4B (GE Healthcare) according to the manufacturer’s 
instructions.  Purified protein was used to immunize rabbits (Cocalico Biologicals 
Inc). 
 
Western blotting. Tissue lysates were prepared in lysis buffer consisting of 20 mM 
Tris HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 
1 µg/ml leupeptin, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM β-
glycerophosphate. 1mM PMSF was added before use. Samples were separated by 
SDS-PAGE and transferred to PVDF membranes. We used antibodies to Gapdh 
(1:5,000 dilution, Chemicon, MAB374), phospho-Gsk3β (Ser 9), total Gsk3β, 
phospho-Akt (Ser 473), total Akt (1:1000 dilution, Cell Signaling, #9336, #9315, 
#4058, #9272). Primary antibody binding was visualized by using the Western Breeze 
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Kit (Invitrogen) according to the manufacturer’s instructions. Inpp5f antibody was 
purified by Melon Gel IgG Spin Purification kit (Thermo Scientific) and then diluted 
1:100 in 5% milk. 
 
Treatment with isoproterenol. Isoproterenol (Sigma, I5627) was delivered by 
implanting a micro-osmotic pump (Alzet, Durect; model 1002) subcutaneously under 
pentobarbital anesthesia. ISO (30 mg/kg/d) or vehicle (Dulbecco’s phosphate buffered 
saline, Gibco) was infused subcutaneously for 14 days as described previously13. 
 
Histology: Adult mouse hearts were collected in ice-cold PBS, fixed overnight in 4% 
paraformaldehyde at 4°C, washed with PBS, and dehydrated through an ethanol series 
prior to paraffin embedding. Masson’s Trichrome (to reveal fibrosis) and H&E stains 
were performed according to standard protocols.  
 
β-galactosidase assay: β-galactosidase activity is measured by Galacto-Light (Tropix, 
BL100G). Activity was expressed as units/mg protein. 
 
Apoptosis analysis. Apoptosis was measured by TUNEL assay (Roche, 1684795). 
The total number of cells was quantified using ImageJ software. 
 
Quantitative real time PCR. Total RNA was isolated from dissected mouse hearts 
using Trizol (Invitrogen).  RNA was reverse-transcribed using random hexamers and 
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the Superscript First Strand Synthesis Kit (Invitrogen). Gene expression was then 
evaluated by qRT-PCR (ABI PRISM 7900) using the SYBR Green (Applied 
Biosystems).  Signals were normalized to their corresponding Gapdh controls and the 
ratios expressed as fold changes compared to wild-type.  PCR conditions and primer 
set sequences are available upon request.  
 
IGF-1 treatment. Hearts from one-month old mice were minced and incubated with 
100nM Insulin like growth factor 1 (IGF-1) (Sigma, I8779) for 30 min at 37oC 
followed by lipid extraction. 
 
PIP3 ELISA. Mouse heart tissue was pulverized under liquid nitrogen using a mortar 
and pestle, followed by lipid extraction and ELISA assays as per manufacture’s 
instruction (Echelon Biosciences Inc, K-2500). ELISA measurements were performed 
in triplicate after combining tissue from 4 hearts. . 
 
Inpp5f-/- knockout mice. Inpp5f+/+ and Inpp5f–/– mice were genotyped by PCR using:  
Wt F: 5' -AAAGCAGGTTGTGAAGTGGAGCTG- 3',  
Wt R: 5' -TGCTCTTGTCATCATCCGAGGACT- 3',  
Mut F: 5' -ATATTGAAACCCACGGCATGGTGC- 3' and  
Mut R: 5' -TTTGATGGACCATTTCGGCACAGC- 3' primers.  
The mutant mice have one band at 323 bp, and the wild type mice have one band at 
1039 bp. 
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The loss of Inpp5f was confirmed by qRT-PCR using  
5' -ACAGGAGAAAGGAAGTTGGCAGGA -3' and  
5' -AGCTTCATGCTCCTTCTCCTTGGT -3' primers. 
 
Inpp5f-transgenic mice. Genotyping was performed by PCR analysis of genomic 
DNA using 5'-TCTTCCAAGCCAAGGACCACTACA- 3' and 5' - 
TCTGCACGGAATTGGTCAGGTCAT- 3', and cardiac specific expression of Inpp5f 
was revealed by qRT-PCR using 5' -ACAGGAGAAAGGAAGTTAGCAGGA- 3' and 
5' -AGCTTCATGTTCTTTCTCCTTGGT- 3' primers. 
 
Inpp5f antibody generation. The primers for amplifying mouse Inpp5f cDNA are 5'-
CGGACTGGCTTCACAAAGCCCA-3', 5'-AGGAGGCGTCTGTCCCATTGGT-3'. 
 
 
Statistic analysis. All data are expressed as the mean ± SD. Student’s t test was used 
to compare heart to body weight ratios and heart weight to tibia length ratios. 
Probability values <0.05 were considered statistically significant. 
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Table 2.1: Loss of Inpp5f does not lead to embryonic or perinatal lethality. 
 
 
 
 
 
 
 
 
 
Reproduced from (Zhu et al., 2009).  
Genotype 
(offspring of 
heterozygous 
crosses) 
P0~P21 
Expected Observed 
Inpp5f +/+ 105 123 
Inpp5f +/- 210 192 
Inpp5f -/- 105 105 
Total 420 420 
χ
2
=4.629, 2 DOF, p=0.10 
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Table 2.2 Inpp5f-/- mice have normal cardiac function by echocardiography. 
 
2 months 9 months 
wild type 
(n=3) 
Inpp5f KO 
(n=3) 
p Value 
wild type 
(n=4) 
Inpp5f KO 
(n=4) 
p Value 
IVSd (mm) 0.69+0.06 0.66+0.03 ns 0.66+0.06 0.67+0.07 ns 
IVSs (mm) 1.13+0.12 1.00+0.04 ns 0.96+0.10 1.02+0.09 ns 
LVPWd (mm) 0.69+0.06 0.64+0.07 ns 0.65+0.03 0.70+0.06 ns 
LVPWs (mm) 1.02+0.13 0.90+0.07 ns 0.95+0.14 1.04+0.07 ns 
LVIDd (mm) 3.92+0.16 3.76+0.13 ns 4.13+0.22 4.13+0.48 ns 
LVIDs (mm) 2.57+0.10 2.54+0.17 ns 2.98+0.12 2.92+0. 40 ns 
LVEF (%) 64+2 60+4 ns 56+4 57+4 ns 
LVFS (%) 34+1 31+3 ns 29+3 29+2 ns 
ns: not significant 
 
Reproduced from (Zhu et al., 2009). This data was produced in collaboration with 
L.Yuan at the Physiology Core of the Cardiovascular Institute at the University of 
Pennsylvania. 
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Table 2.3: Echocardiography of wild type and Inpp5f-/- mice after 2 weeks of 
ISO infusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from (Zhu et al., 2009).  
 
2 months 
wild type 
(n=5) 
Inpp5f KO 
(n=5) 
p Value 
IVSd (mm) 0.69+0.10 0.78+0.15 ns 
IVSs (mm) 1.01+0.17 1.16+0.25 ns 
LVPWd (mm) 0.65+0.06 0.74+0.06 0.04 
LVPWs (mm) 0.98+0.13 0.98+0.16 ns 
LVIDd (mm) 3.97+0.36 3.96+0.45 ns 
LVIDs (mm) 2.80+0.45 2.76+0.60 ns 
LVEF (%) 57+12 59+12 ns 
LVFS (%) 30+8 31+8 ns 
57 
 
Table 2.4: Genotyping result from Hdac2+/-, Inpp5f+/- intercross (N=75). 
 
Genotype N 
Hdac2 +/+ Inpp5f +/+ 8 
Hdac2 +/+ Inpp5f +/- 10 
Hdac2 +/+ Inpp5f -/- 7 
Hdac2 +/- Inpp5f +/+ 9 
Hdac2 +/- Inpp5f +/- 24 
Hdac2 +/- Inpp5f -/- 11 
Hdac2 -/- Inpp5f +/+ 4 
Hdac2 -/- Inpp5f +/- 2 
Hdac2 -/- Inpp5f -/- 0 
  
58 
 
Table 2.5: Genotyping result from Akt+/-, Inpp5f+/- intercross (N=86). 
 
Genotype N 
Akt +/+ Inpp5f +/+ 10 
Akt +/+ Inpp5f +/- 13 
Akt +/+ Inpp5f -/- 6 
Akt +/- Inpp5f +/+ 10 
Akt +/- Inpp5f +/- 21 
Akt +/- Inpp5f -/- 15 
Akt -/- Inpp5f +/+ 5 
Akt -/- Inpp5f +/- 6 
Akt -/- Inpp5f -/- 0 
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Reproduced from (Trivedi et al., 2007). 
Figure 2.1: Inpp5f regulates PI3K/Akt pathway in vitro. 
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Figure 2.1: Inpp5f regulates PI3K/Akt pathway in vitro.  
(A) Overexpression of Inpp5f in H9C2 cells resulted in decreased phosphorylation of 
Gsk3β and Akt. Phosphorylated and total Gsk3β and Akt were measured by Western 
Blot with or without transfection of Inpp5f and caAkt expression vectors. (B) H9C2 
cells were treated with siRNA to knockdown Inpp5f, and total and phosphorylated 
Akt levels were measured by Western Blot. 
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Figure 2.2: Generation and confirmation of Inpp5f antibodies. 
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Figure 2.2: Generation and confirmation of Inpp5f antibodies.  
A. Coomassie blue staining of the GST fusion protein. Lane 1, maker; Lane 2, 
unpurified protein; Lane 3, GST only; Lane 4, GST fused with epitope N; Lane 5, 
GST fused with epitope C. B. Tranfection of Cos7 cells with epitope tagged plasmid 
to determine the size of Inpp5f protein. Lane 1, control cell protein; Lane 2, FLAG-
tagged Inpp5f transfected cell protein; Lane 3, MYC-tagged Inpp5f transfected cell 
protein. C. Examination of 4 sera on both Flag-tagged Inpp5f containing plasmid 
(Lane 1, 3, 5, 7) and empty vector transfected cells (Lane 2, 4, 6, 8).  
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Reproduced from (Zhu et al., 2009). 
Figure 2.3: Inactivation of Inpp5f. 
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Figure 2.3: Inactivation of Inpp5f.  
(A) Schematic representation of Inpp5f protein (top) and gene structure.  The wild 
type and gene trap alleles are shown; exons are represented by black boxes. The sizes 
of the expected restriction fragments recognized by the Southern probe (indicated) are 
shown. (B) Southern blot of adult mice tail DNA resulting from a cross between 
Inpp5f+/-heterozygotes. (C) PCR genotyping of offspring resulting from a cross 
between Inpp5f +/-heterozygotes. (D) Real-time quantitative PCR of mRNA from adult 
wild-type and Inpp5f-/- hearts shows the absence of Inpp5f mRNA in the knockout 
hearts. (E) Western blot of wild-type and Inpp5f-/- adult heart tissue shows loss of 
Inpp5f protein in mutant hearts. 
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Figure 2.4: Confirmation of genetrap insertion and existence of fusion mRNA. 
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Figure 2.4: Confirmation of genetrap insertion and existence of fusion mRNA.  
(A) Schematic of Inpp5f genomic DNA and the predicted genomic locus following 
the genetrap cassette insertion. The primers for PCR are shown. (B) PCR results from 
knockout and wildtype mice using 4 different reverse primers are shown. (C) 
Schematic representation of the Inpp5f fusion mRNA transcript. The primers for the 
Real-time PCR are shown. (D) Real-time RCR of mRNA from four individual 
knockout mice and their wild type littermate controls using primers shown in (C). 
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Figure 2.5: Examination of the endogenous Inpp5f genomic sequence. 
 
Reproduced from (Zhu et al., 2009). 
68 
 
Figure 2.5: Examination of the endogenous Inpp5f locus and the targeted locus.  
Primers specific for each exon (4-20) were used to determine if the genomic sequence 
corresponding to these exons was present in the wildtype and homozygous mutant 
genome. PCR results show that exon 7 to 13 are deleted in the Inpp5f homozygous 
mutant genome. 
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Reproduced from (Zhu et al., 2009). 
Figure 2.6: Inpp5f -/- hearts appear normal. 
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Figure 2.6: Inpp5f -/- hearts appear normal.  
(A) H&E-stained sections of wild-type and Inpp5f-/- hearts at E14.5, E16.5 and P65 
(scale bar, 400 µm) reveals normal heart structure. (B) Heart to body weight and heart 
to tibia length ratios of Inpp5f+/+ (n = 8) and Inpp5f -/- (n = 12) mice at 2 month of age. 
(C) Heart to body weight and heart to tibia length ratios of Inpp5f+/+ (n = 4) and 
Inpp5f -/- (n = 4) mice at 9 month are shown. NS: not significant. 
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Adapted and modified from (Zhu et al., 2009). 
Figure 2.7: Inpp5f-deficient mice are susceptible to agonist-induced cardiac 
hypertrophy. 
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Figure 2.7: Inpp5f-deficient mice are susceptible to agonist-induced cardiac 
hypertrophy. 
(A) Wild-type and Inpp5f-/- littermates were subjected to chronic infusion of saline or 
ISO for 14 days. Heart weight to body weight and heart weight to tibia length ratios 
(± s.d.) were determined. (B) Transcripts for Nppa, Nppb and Myh7 were detected by 
real-time quantitative PCR in hearts from wild-type and Inpp5f-/- mice following 
chronic infusion of saline or ISO. The values are expressed as the fold change in 
transcript abundance (± s.d.) compared to wild-type mice. (C) Wheat germ agglutinin 
(WGA) staining shows increased myocyte size in Inpp5f-/- compared to wild-type 
hearts (scale bar, 25 µm). (D)Trichrome staining demonstrates more fibrosis (blue) in 
Inpp5f-/- hearts treated with ISO (scale bar, 150 µm,) compared to control. (E) Western 
blots from neonatal cardiomyocytes treated with or without 10 µM ISO for 10 min are 
shown; Gapdh is shown as a loading control.  
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Adapted and modified from (Zhu et al., 2009). The mass spec data was obtained in 
collaboration with Dr Andrew Quong at Tomas Jefferson University. 
Figure 2.8: PIP3 levels are altered in the Inpp5f knockout mice. 
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Figure 2.8: PIP3 levels are altered in the Inpp5f knockout mice.  
(A) Mass spec results from lipid extracts of 4 heart samples. Peak 886 (red circle) 
represents PIP3. (B) PIP3 levels, normalized to heart weight, in the Inpp5f-/- and 
wildtype hearts after 30 min of 100 nM IGF-1 stimulation were assayed as indicated 
in “Materials and Methods”.  
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Adapted and modified from (Zhu et al., 2009). 
Figure 2.9: Generation of Inpp5f transgenic mice. 
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Figure 2.9: Generation of Inpp5f transgenic mice.  
(A) Schematic representation of the Inpp5f transgenic constructs. (B) PCR genotyping 
result for both constructs. 6 lines for IRES-EGFP and 2 lines for Flag construct are 
shown. 1 positive control and 2 negative controls are also shown. (C) Western blot 
analysis of myocardium from 2-month-old wild-type and Inpp5f-Tg mice. 
Transgenically expressed Inpp5f was epitope-tagged and was detected using an Inpp5f 
antibody and a Flag antibody. Arrow: Inpp5f protein. (D) Western Blot to detect the 
expression of GFP. Heart protein lysates from 6 lines of IRES-EGFP were extracted 
and probed with GFP antibody. The last lane is a positive control showing the 
expression of GFP. 
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Adapted and modified from (Zhu et al., 2009). 
Figure 2.10: Inpp5f-Tg mice are resistant to agonist-induced cardiac hypertrophy. 
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Figure 2.10: Inpp5f-Tg mice are resistant to agonist-induced cardiac hypertrophy.  
(A) Wild-type and Inpp5f-Tg littermates were subjected to chronic infusion of saline 
or ISO for 14 days. Heart weight to body weight and heart weight to tibia length ratios 
(± s.d.) were determined. (B) Transcripts for Nppa, Nppb and Myh7 were detected by 
real-time quantitative PCR from hearts of wild-type and Inpp5f-Tg mice following 
chronic infusion of saline or ISO. The values are expressed as the fold change in 
transcript abundance (± s.d.) compared to wild-type mice. (C) Western blots of 
myocardium from 2-month-old wild-type and Inpp5f-Tg mice subjected to infusion of 
saline or ISO for 14 days. Gapdh is shown as a loading control. 
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Figure 2.11: Inpp5f has a Sac domain and it has the conserved catalytic motifs. 
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Figure 2.11: Inpp5f has a Sac domain and it has the conserved catalytic motifs. 
The Sac domain contains seven highly conserved motifs, including the putative 
catalytic RXNCXDCLDRTN motif (conserved motif 6, shown in red). These are 
shown for the human Inpp5f, mouse Inpp5f and the yeast Sac domain-containing 
proteins Sac1p and Inp51p. 
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Figure 2.12: Inpp5f does not interact with PDK1. 
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Figure 2.12: Inpp5f does not interact with PDK1 . (A) Western blot shows the 
expression of two proteins in transfected Cos7 cells. (B) The proteins were extracted 
from transfected Cos7 cells. Co-immunoprecipitation was performed with an anti-
Myc antibody. Inpp5f did not interact with PDK1 when immunoprecipated with an 
anti-Myc antibody and detected with anti-Flag antibody. Input control is shown on the 
left. Immunoblot (IB) of Myc control is shown at the bottom. 
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Chapter 3 Regulation of Gata4 deacetylation and stability by Hdac2 
Some of this Chapter has been published in (Trivedi et al.). 
 
3.1 Summary 
In chapter 2, I examined the effects of gain and loss of Inpp5f in the heart, 
which might function downstream of Hdac2. However, Hdac2 nulls also display 
enhanced cardiac myocyte proliferation during embryonic stages, which I did not 
observe in Inpp5f mutant mice. This suggests that mechanisms unrelated to Inpp5f 
might be responsible for the embryonic phenotypes of Hdac2 nulls. In this chapter, I 
describe that Hdac2 and Gata4 physically interact and I map the Gata4 interaction 
domain. I also investigate the function of acetylation on Gata4 stability.  
 
3.2 Introduction 
Gata4 is one of the earliest genes expressed by specified cardiac precursors at 
the cardiac crescent stage of the mouse development (Arceci et al., 1993; Kelley et al., 
1993). Global loss of Gata4 in mice causes embryonic lethality at E9.5 as a result of 
severe defects in the extra-embryonic endoderm and aberrant heart and foregut 
morphogenesis (Kuo et al., 1997; Molkentin et al., 1997). Studies involving tissue-
specific loss of Gata4 in murine cardiac myocytes have demonstrated a critical role 
for Gata4 in embryonic myocyte proliferation (Zeisberg et al., 2005). Mice lacking 
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Gata4 in the anterior heart field (AHF), for example, die by E13.5 due to significant 
right ventricular and interventricular septal myocyte proliferation defects (Rojas et al., 
2008). Gata4-null cardiomyocytes show down-regulation of a wide array of cell cycle 
associated genes, some of which are direct transcriptional targets of Gata4, including 
cyclinD2 and cdk4 (Rojas et al., 2008).  
Recently, we have shown that global loss of HDAC2 results in partial perinatal 
lethality due to cardiac developmental defects that include enhanced cardiac myocyte 
proliferation (Trivedi et al., 2007). Microarray and RT-PCR analysis suggested that 
several cell cycle genes were up-regulated in Hdac2 null hearts at E16.5, including 
transcripts of known Gata4 targets, cyclin-D2 and cdk4. Interestingly, Gata4 protein 
levels were unaltered in the knockout hearts (unpublished data).  
Gata4 transcriptional activity is known to be regulated by post-translational 
modification including acetylation, phosphorylation and sumoylation (Kawamura et 
al., 2005; Liang et al., 2001a; Wang et al., 2004). For example, the histone acetyl 
transferase (HAT) p300 is able to acetylate Lys311, 318, 320, and 322 of Gata4, 
resulting in enhanced DNA binding and transcriptional activity. In transgenic mice, 
p300 over-expression in the heart induces Gata4 acetylation and cardiac hypertrophy 
(Miyamoto et al., 2006; Yanazume et al., 2003a). Interestingly, p300 null mice die at 
E9.5 exhibiting defects in proliferation and cardiac development (Yao et al., 1998). 
Mechanisms for Gata4 deacetylation have, to our knowledge, not been previously 
described. This leads us to hypothesize that Hdac2 might deacetylate Gata4 and thus 
85 
 
regulates it transcriptional activity. As an initial step to test this hypothesis, I 
investigated the interaction between Gata4 and Hdac2. My results suggest that Gata4 
is able to interact with Hdac2 and the lysine rich domain of is responsible for the 
interaction. 
The present study focused on the role of Hdac2 during embryonic cardiac 
development.  However, our prior studies have implicated important roles for Hdac2 
in the adult heart (Kook et al., 2003; Trivedi et al., 2007).  Gata4 also functions in 
homeostasis of the adult myocardium, and alterations in transcriptional activity, 
including those regulated by p300-mediated acetylation of Gata4, affect adult cardiac 
hypertrophy (Dai and Markham, 2001; Hirai et al., 2004; Yanazume et al., 2003a; 
Yanazume et al., 2003b).  However, the model presented here to explain the roles of 
Hdac2 and Gata4 in regulation of embryonic myocardial proliferation cannot easily 
explain the roles for these proteins during adult cardiac hypertrophic processes.  
Hdac2 deficiency results in resistance to cardiac hypertrophy.  Cardiac hypertrophy is 
generally associated with enhanced Gata4 activity, which drives cardiac structural 
gene expression.  A simple extension of the model presented here would suggest that 
loss of Hdac2 would result in enhanced Gata4 activity, which is not consistent with 
the adult phenotypes.   However, we have noted a dramatic loss of Gata4 protein in 
newborn mice lacking Hdac2 (unpublished data), suggesting that hyper-acetylation 
results in protein degradation, with resulting loss of Gata4 activity.  This would be 
consistent with the adult phenotypes we have observed. Actually, a previous study has 
provided evidence that acetylated GATA-1 is targeted for degradation via the 
86 
 
ubiquitin/proteasome pathway and activation by acetylation simultaneously marks 
GATA-1 for degradation (Hernandez-Hernandez et al., 2006). The other part of my 
study is to elucidate the mechanisms by which acetylation of Gata4 leads to 
degradation. My preliminary results suggest that deacetylation of Gata4 by Hdac2 
stabilizes Gata4.  
 
3.3 Results 
3.3.1 Hdac2 and Gata4 physically interact 
Other Gata factors have been shown to be able to recruit Hdacs to regulate gene 
expression (Cantor and Orkin, 2005; Hong et al., 2005; Svensson et al., 1999; Tsang 
et al., 1997). For example, Hdac3 interacts with Gata2 to regulate transcriptional 
repression in hematopoietic progenitor cells (Ozawa et al., 2001). Gata1 recruits 
Hdac5 leading to reduced Gata1 transcriptional activity (Watamoto et al., 2003). In 
order to test if Gata4 and Hdac2 can physically interact with each other, I transfected 
293 cells with HA-tagged Gata4. Total lysates were immunoprecipitated by anti-HA 
antibody to immunoprecipitate Gata4 and Western blot analysis was performed with 
Hdac2 antibody. The data suggest that Gata4 and Hdac2 can interact (Fig 3.1).  
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3.3.2 The interaction between Hdac2 and Gata4 requires the lysine rich domain 
of Gata4 
The protein structure for Gata4 has been widely studied. It contains a domain of 
two adjacent zinc fingers (Cys-X2-Cys-X17-Cys-X2-Cys) that directs preferential 
binding to the nucleotide sequence element 5’-(A/T)GATA(A/G)-3’ of target gene 
promoters (Pikkarainen et al., 2004). A lysine rich motif is present in between the two 
zinc fingers and two separate transcriptional activation domains are present within the 
N terminus of the protein (Morrisey et al., 1997). In order to identify the Hdac2 
interaction domain in Gata4, eight Gata4 N-terminal deletion constructs and four C-
terminal deletion constructs were made (Fig 3.2A). Expression analysis shows that 
three of the N-terminal deletion constructs and all four C-terminal deletion constructs 
expressed (Fig 3.2B). Co-immunoprecipitation experiments showed that all seven 
expressed constructs were able to interact with Hdac2 (Fig 3.3).  Because all 
constructs have a common region amino acid 241-274 (Fig 3.2A), I hypothesized that 
this is the region that is responsible for the interaction. I then tried to optimize the 
transfection conditions for two N-terminal deletion constructs which do not contain 
region 241-274 (∆265, ∆294).  However, by adjusting the DNA/superfect ratio and 
incubation time, I failed to detect any expression (data not shown). Similarly, an N-
terminal deletion construct with the first 240 aa did not express either (data not 
shown). I then made an internal deletion construct in which amino acids 241-274 were 
absent using a technique called splicing overlap extension PCR (Fig 3.4A). I 
confirmed the expression of the protein by Western blot (Fig 3.4B). However, the 
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expression level of this construct is much lower than the full length construct. I 
optimized the transfected DNA amount, DNA/superfect ratio as well as incubation 
time. Unfortunately, I found that these factors did not improve the expression level 
(Fig 3.5). Therefore, I diluted the full length Gata4 transfected cell lysate using the 
untransfected lysate so that the expression levels of the full length Gata4 and the 
internal deletion are similar (Fig 3.6A). This construct was unable to bind Hdac2 (Fig 
3.6B).  Therefore, our data suggest that Gata4 is able to interact with Hdac2 and the 
lysine rich motif 241-274 in Gata4 is responsible for this interaction. 
 
3.3.3 Deacetylation of Gata4 by Hdac2 stabilizes Gata4 
I hypothesized that acetylation of Gata4 positively signals ubiquitination and 
degradation in the heart. I first transfected H9c2 cells, a cardiomyocyte cell line, with 
HA-tagged Gata4 and then treated them with cycloheximide (CHX) after 48 hours to 
inhibit further protein synthesis. I measured Gata4 decay by Western blots and found 
that after 9 hrs, the protein disappeared by half and after 28 hrs, it was almost 
completely degraded (Fig 3.7). However, one caveat for this approach is that the 
protein half-life is measured when overall protein synthesis is abrogated and thus may 
not reflect the actual turnover rate under normal growth conditions. The stability and 
abundance of the proteolytic enzymes themselves might also be affected, which 
further complicates the accurate measurement of protein turnover rate. Therefore, I 
also used pulse chase as an alternative method, which imposes minimal disruption 
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with normal cell growth and metabolism. H9c2 cells were transfected with HA-Gata4 
and cells were metabolically labeled for 30 min with [35S] methionine/cysteine. The 
cells were harvested after 0, 2, 6, 11h of chase. This experiment gave me the time 
frame to measure Gata4 stability. The result suggested that after 2 h of chase, the 
amount of Gata4 showed a reduction of ~70% (Fig 3.8A). I then hypothesized that co-
transfection with Hdac2 leads to increased Gata4 stability. Western blot showed over-
expression of Hdac2 in the co-transfected cells (Fig 3.8C), while Gata4 is expressed at 
equal amount (data not shown). Preliminary pulse chase results suggest that Hdac2 
stabilizes Gata4 though this experiment needs to be repeated for statistical analysis 
(Fig 3.8B). 
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3.4 Discussion 
In this chapter, I demonstrated that Gata4 is able to interact with Hdac2 and the 
lysine rich domain located between the two zinc fingers is necessary for interaction. 
My preliminary results also suggest that deacetylation of Gata4 by Hdac2 might play 
a role in Gata4 stability. 
Gata4 contains two distinct zinc finger domains and a C-terminal nuclear 
localization sequence that together constitute the DNA binding and protein-protein 
interaction domain (Molkentin, 2000). Gata4 also contains two transcriptional 
activation domains in the N-terminus (Pikkarainen et al., 2004). Gata4 has been 
shown to cooperate with a number of other transcription factors and co-activators. 
Specifically, the C-terminal zinc finger domain has been found to interact physically 
with several other factors to regulate cardiac gene promoters including p300, dHAND, 
Nkx-2.5 and NFAT (Dai et al., 2002; Dai and Markham, 2001; Lee et al., 1998; 
Molkentin et al., 1998). However, a co-repressor protein FOG-2 (friend of Gata-2) 
interacts with N-terminal zinc finger, and Gata6 may require both zinc fingers for 
their interaction (Charron et al., 1999; Lu et al., 1999; Svensson et al., 2000; Svensson 
et al., 1999; Tevosian et al., 1999). My studies identify the lysine rich domain located 
between the two zinc fingers as the region necessary for interaction with Hdac2. 
Previous reports have indicated that Gata factors can recruit Hdacs to target 
genes, either by directly interacting or by associating with Fog proteins that can 
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recruit the NuRD complex containing Hdac1 and Hdac2 (Cantor and Orkin, 2005; 
Hong et al., 2005; Svensson et al., 1999; Tsang et al., 1997). For example, interaction 
of Hdac3 with Gata2 leads to transcriptional repression of Gata2 in hematopoietic 
progenitor cells (Ozawa et al., 2001). Similarly, Hdac5 interacts with Gata1 and 
represses its transcriptional activity (Watamoto et al., 2003). In each case, Hdac 
function suppresses Gata dependent transcriptional activity. Although it was generally 
assumed that Hdac-mediated transcriptional repression of Gata activity was mediated 
by histone deacetylation and chromatin remodeling, it will be interesting to re-address 
this question in light of our results to determine if other Gata proteins are regulated by 
Hdacs via direct deacetylation. 
Acetylation has been shown regulate protein stability in two opposing ways. 
Lysines are targets for both acetylation and ubiquitination. Therefore, acetylation can 
stabilize proteins by preventing subsequent ubiquitination (Kouzarides, 2000) as 
demonstrated for both p53 (Li et al., 2002) and Smad7 (Gronroos et al., 2002). 
However, the opposite possibility also exists: acetylation at some lysines might 
positively signal ubiquitination at other lysines to thus cause protein loss. For example, 
acetylated GATA-1 is targeted for degradation via the ubiquitin/proteasome pathway 
and activation by acetylation simultaneously marks GATA-1 for degradation 
(Hernandez-Hernandez et al., 2006). Therefore, a lysine mutated construct of Gata4 is 
of limited use in studying the effect of acetylation on Gata4 stability. In my study, I 
used Hdac2 co-transfection with Gata4. Alternative methods such as p300 co-
transfection and Hdac2 inhibitor can also be performed to examine the effect of 
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acetylation on Gata4 stability. 
 
3.5 Materials and methods 
Immunoprecipitation. 293 cells were homogenized in immunoprecipitation buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 mM 
DTT) containing 1 mM PMSF, phosphatase inhibitors (Sigma), and protease 
inhibitors mixture (Sigma). The samples were sonicated five times for 3 s. The lysate 
was collected by centrifugation at 16,000 X g for 10 min at 4°C. Pre-cleared lysates 
with beads were incubated with primary antibodies for 16 h at 4°C. After incubation 
for 1 h at 4°C with beads, immunocomplexes were collected, washed three times with 
immunoprecipitation buffer at 4°C, and applied to 4-12% SDS-polyacrylamide gels 
for Western blot analysis. 
 
Western blotting. Tissue lysates were prepared in lysis buffer consisting of 20 mM 
Tris HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 
1 µg/ml leupeptin, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM β-
glycerophosphate. 1mM PMSF was added before use. Samples were separated by 
SDS-PAGE and transferred to PVDF membranes. We used antibodies to Gapdh 
(1:5,000 dilution, Chemicon, MAB374), HA (1:1000 dilution, SantaCruz) and Hdac2 
(1:1000 dilution, Invitrogen). Primary antibody binding was visualized by using the 
Western Breeze Kit (Invitrogen) according to the manufacturer’s instructions. 
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Transient transfections. H9c2 myoblasts and 293 cells were transfected with 
SuperFect reagent (Qiagen) as per manufacturer's protocol.  
 
Plasmids and deletion constructs cloning. Plasmids for expression of Hdac2 and 
Gata4 are previously described (Durocher et al., 1997; Kook et al., 2003; Trivedi et al., 
2007). Various deletion mutants of HA tagged Gata4 cDNA were created by PCR 
amplification, sequence verified, and subcloned into the pGC eukaryotic expression 
vector. Primers sequences for Gata4 deletion constructs are as follows: 
N terminal deletion constructs: 
Reverse primer is 5'-TTACGCGGTGATTATGTCCC-3' 
Forward primer: 
∆80: 5'- 
GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGGACCCAGCAGGGTA
G-3' 
∆129: 5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTGCAGCCTACAGCAGTAG
C-3' 
∆183: 5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTTTCGACAGCCCAGTCCT
G-3' 
∆209: 
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5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTTTCTCAGAAGGCAGAG
AGTGT-3' 
∆240: 5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGCCTCTACCACAAGAT
GAAT-3' 
∆265: 
5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTGTAGGCCTCTCCTGTGC
C-3' 
∆294: 
5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGCCTCTACATGAAGCT
CC-3' 
∆329: 
5'- 
GCCACCatgTACCCATACGATGTTCCAGATTACGCTCCAGCAGGTCCTCCTGG
-3' 
C terminal deletion constructs: 
Forward primer is 5'-
GCCACCatgTACCCATACGATGTTCCAGATTACGCTTACCAAAGCCTGGCTAT
G-3' 
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Reverse primer:  
∆391-440: 5'-TTAGCCGGACACAGTACTGAATGT-3' 
∆337-440: 5'-TTACTCGCCAGGAGGACCTG-3' 
∆311-440: 5'-TTACCGCATTGCAAGAGGCCT-3' 
∆275-440: 5'-TTACTGGCAGTTGGCACAGGA-3' 
 
Splicing overlap extension PCR. The PCR methods are previously described 
(Warrens et al., 1997). Primers sequences for the splicing overlap extension PCR are 
as follows: 
Gata4 primer A: 5’-ATG TAC CAA AGC CTG GCT AT-3’ 
Gata4 primer B hybrid: 5’-CAG TGT GGT GGT GGT AGT ACA GGC GTT GCA 
TAG GTA-3’ 
Gata4 primer C hybrid: 5’-TAC CTA TGC AAC GCC TGT ACT ACC ACC ACC 
ACA CTG-3’ 
Gata4 primer D: 5’-TTA CGC GGT GAT TAT GTC CC-3’ 
 
Pulse chase. Cells were starved for 30 min in 2 ml of methionine/cysteine-free 
medium (Invitrogen) at 37oC, metabolically labeled for 30 min with 125 µCi/ml of 35S 
methionine/cysteine (pulse), washed free of unbound radioactive amino acids, and 
incubated in prewarmed complete medium (chase). At the indicated time points, the 
cells were disrupted in ice-cold lysis buffer and immunoprecipitated with anti-HA 
antibody. Proteins were subjected to SDS-PAGE. Labeled proteins were visualized 
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and quantitatively analyzed with phosphor imager. 
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Figure 3.1: Hdac2 and Gata4 physically interact. 
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Figure 3.1: Hdac2 and Gata4 physically interact. 
293 cells were transfected with HA-Gata4. Immunoprecipitation were performed by 
anti- HA antibody to immunoprecipitate Gata4 and western blot analysis was 
performed with Hdac2 antibody to detect the endogenous Hdac2. n.s. non-specific 
band. 
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Adapted and modified from (Trivedi et al.). 
Figure 3.2: Generation of 12 Gata4 deletion constructs. 
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Figure 3.2: Generation of 12 Gata4 deletion constructs. 
(A) Schematic representation of Gata4 and deletion constructs. (B) Western blot was 
performed to examine the expression of the 12 deletion constructs. 7 constructs were 
expressed. 
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Adapted and modified from (Trivedi et al.). 
Figure 3.3: Hdac2 is able to interact with all seven deletion constructs. 
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Figure 3.3: Hdac2 is able to interact with all seven deletion constructs. Total 
lysates from Gata4 or various Gata4 deletion constructs transfected 293 cells were 
immunoprecipitated with anti-HA antibody and Western blot analysis was performed 
with anti-Hdac2 antibody to detect endogenous Hdac2. n.s. - non-specific. 
103 
 
  
 
 
Figure 3.4: Generation of a Gata4 internal deletion construct ∆241-274. 
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Figure 3.4: Generation of a Gata4 internal deletion construct ∆241-274. (A) The 
schematic representation of splicing overlap extension PCR. The details are discussed 
in the materials and methods section. cDNAs are represented lined as bars. Modified 
from (Warrens et al., 1997). (B) The internal deletion construct is expressed though at 
a much lower level as detected by Western blot. The H9c2 cells were transfected with 
different amounts of DNA as indicated in the figure. 
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Figure 3.5:  Optimization of ∆241-274 construct transfection conditions. 
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Figure 3.5:  Optimization of ∆241-274 construct transfection conditions. DNA 
amounts, DNA/Superfect ratios and incubation times were adjusted to increase the 
construct expression. 
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Figure 3.6: The internal deletion construct ∆241-274 was unable to interact with 
Hdac2.  
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Figure 3.6: The internal deletion construct ∆241-274 was unable to interact with 
Hdac2. (A) Gata4 full length construct transfected cell lysate was diluted 50 fold with 
untransfected lysate. 50 µg total protein was loaded to compare the level of Gata4 and 
Hdac2. (B) Total lysates from Gata4 or the internal deletion construct ∆241-274 
transfected 293 cells were immunoprecipated with anti-HA antibody and Western blot 
analysis was performed with anti-Hdac2 antibody to detect endogenous Hdac2. ns-
non specific. 
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Figure 3.7:  Blockage of protein synthesis leads to Gata4 degradation. 
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Figure 3.7:  Blockage of protein synthesis leads to Gata4 degradation. 
(A) H9c2 cells were transfected with HA-Gata4. 48 hrs after transfection, the cells 
were treated with 10 µg/ml CHX for indicated time periods. The cells were lysed and 
the protein lysates were subjected to SDS-PAGE. Western blot was performed using 
anti-HA antibody. (B) Quantification of the remaining protein amount. 
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Figure 3.8: Co-transfection with Hdac2 stabilizes Gata4. 
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Figure 3.8: Co-transfection with Hdac2 stabilizes Gata4. (A) H9c2 cells were 
transfected with HA-Gata4. 48 hrs after transfection, the cells were pulse labeled with 
35S and then collected at indicated time points. The protein lysates were 
immunoprecipitated with anti-HA antibody and proteins were subjected to SDS-
PAGE. Labeled proteins were visualized with phosphor imager. The quantification is 
shown on the right. (B) H9c2 cells were transfected with either HA-Gata4 alone or 
HA-Gata4 and Hdac2 both. Pulse chase experiment was performed similarly. (C) 
Western blot confirms the over-expression of Hdac2 in the Hdac2 and Gata4 co-
transfected cells. 
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Chapter 4 Conclusions and Future Directions 
4.1 Summary 
In this dissertation I have investigated the potential mechanisms of Hdac2 in the 
regulation of adult cardiac hypertrophy and embryonic myocyte proliferation. In 
chapter 2, I described the function of a poorly described PIP3 5’ phosphatase Inpp5f 
in cardiac hypertrophic responsiveness. Our prior work (Trivedi et al., 2007) had 
implicated this gene in cardiac hypertrophy because it is regulated by Hdac2, and 
Hdac2 deficiency protects against hypertrophy by modulating the Akt pathway. My 
work directly tests the functions of Inpp5f via both gain and loss of function studies. I 
describe the knockout mouse, and transgenic mice over-expressing Inpp5f in the heart. 
In both cases, the mice are normal under basal conditions, but the response to 
hypertrophic stimuli are abnormal in terms of cardiac size, myocyte size and gene 
expression. This work has important clinical implications.  The lack of basal defects 
suggests that this phosphatase may be a tractable target for therapeutic intervention 
for heart failure. In chapter 3, I studied the potential mechanisms of how Hdac2 might 
regulate myocyte proliferation during embryonic development. My preliminary 
results suggest that Gata4 may be responsible for the hyper-proliferation defects in 
Hdac2 null mice. Hdac2 is able to interact with Gata4. However, since Gata4 also 
functions in homeostasis of the adult myocardium and cardiac hypertrophy is 
generally associated with enhanced Gata4 activity, the model presented in chapter 3 
cannot easily explain its role during adult cardiac hypertrophy. Therefore, in chapter 3, 
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I also sought to study the effects of acetylation on Gata4 stability. My preliminary 
result suggests that deacetylation stabilizes Gata4. In the absence of Hdac2, Gata4 is 
hyper-acetylated leading to more proliferation during embryonic development. 
However, hyper-acetylation also marks Gata4 for degradation, which explains the 
significant down-regulation of Gata4 levels after birth. Many critical questions still 
remain for Inpp5f, Gata4 and Hdac2 and I discuss below several aspects that I feel 
worth further investigation. 
 
4.2 Future directions 
4.2.1 Inpp5f, a tumor suppressor? 
My results suggest that Inpp5f negatively regulates the PI3K/Akt pathway in 
vivo. The PI3K/Akt pathway activation initiates a signal transduction cascade that 
promotes cell growth, survival and metabolism. The abnormal activation of this 
pathway has been validated by epidemiological and experimental studies as an 
essential step toward the initiation and maintenance of human tumors (Garcia-
Echeverria and Sellers, 2008). PTEN, a negative regulator of this pathway, acts as a 
tumor suppressor. It is mutated or lost in both heritable and spontaneous cancers. 
Germline mutations in PTEN cause autosomal dominant hamartoma tumor syndromes, 
whereas sporadic missense mutations occur frequently in central nervous system 
(20%), endometrial (39%), colorectal (9%), skin (17%), prostate (14%) and breast 
(6%) cancers. Monoallelic loss of PTEN contributes to tumor growth in the context of 
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other somatic mutations, and PTEN protein levels correlate with disease severity 
(Yuan and Cantley, 2008). When I first got the Inpp5f null mice, I expected that they 
would develop some kind of tumors as they age. However, I did not observe any sign 
of cancer in these mice. PTEN is considered the principal regulator of basal cellular 
PtdIns(3,4,5)P3 levels (Leslie and Downes, 2002). Other PIP3 phosphotases only 
allow for greater pathway activity upon Akt stimulation. For example, a single 
somatic missense mutation in the phosphatase domain of SHIP1 has been identified in 
patients with acute myeloid leukemia which reduced the catalytic activity of SHIP1. 
The basal level of Akt phosphorylation was comparable between leukemia cells with 
and without the mutation. However, leukemia cells with this mutation showed 
enhanced Akt phosphorylation following stimulation (Luo et al., 2003). Besides, 
Ship2 has been reported to be a negative regulator of Akt activation. Although loss of 
Ship2 is not sufficient to activate Akt, the absence of Ship2 allows for greater activity 
upon Akt stimulation (Rommel et al., 2001; Wada et al., 2001). Therefore, it is very 
possible that unlike PTEN, which as a stringent regulator attenuates PtdIns(3,4,5)P3 
signaling, the 5-phosphatases could function as more subtle modulators of the 
PtdIns(3,4,5)P3 signals. It would be interesting to see if Inpp5f increases tumor 
development in a Pten null or heterozygous background. Other 5’ phosphatases may 
be able to compensate for Inpp5f under the relatively sedentary conditions under non-
stressed situations. It would also be informative to test if loss of Inpp5f in 
combination with loss of Ship1 and/or Ship2 would result in cancer. 
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4.2.2 Inpp5f, a poorly characterized 5’ phosphatase 
In chapter 2, I demonstrated that Inpp5f was able to degrade PIP3 in the heart. I 
also identified seven highly conserved motifs and the sixth conserved region of Inpp5f 
in both mouse and human has the highly conserved CX5R(T/S) motif. It would be 
interesting to see if mutations in the cysteine, arginine and threonine/serine residues 
could disrupt its enzymatic activity. We could either transfect the mutated Inpp5f and 
measure Akt level or measure PIP3 levels directly by ELISA. 
 
4.2.3 To what extent does Hdac2 regulate hypertrophy through Inpp5f? 
In chapter 2, I elucidated the role of Inpp5f in regulating cardiac hypertrophy by 
utilizing a gene-trap Inpp5f global knockout mouse model and a cardiac specific over-
expression mouse model. My data suggests that Inpp5f transgenic mice were unable 
to reactivate fetal genes or to exhibit normal hypertrophic responses while Inpp5f 
knockout mice have augmented hypertrophy associated with reactivation of the fetal 
gene program. Biochemical analysis indicated that these responses were mediated by 
the PI3K/Akt pathway. Furthermore, we have also shown that Hdac2 promotes 
cardiac hypertrophy (Trivedi et al., 2007) and that Inpp5f is up-regulated in Hdac2 
knockout hearts, both during late gestation and in the adult while it is down-regulated 
in Hdac2 transgenic mice that over-express Hdac2 in the heart. Hdac2 can deacetylate 
histones at the Inpp5f upstream genomic region, consistent with direct regulation 
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(Trivedi et al., 2007). However, it remains unclear whether Hdac2 regulates 
hypertrophy partially or entirely via Inpp5f. I performed some preliminary crosses 
with Hdac2+/- and Inpp5f -/- to generate Hdac2-/-Inpp5f-/-. Future experiments can 
be done to see if these double knockout mice respond differently to hypertrophic 
stimuli from the Hdac2 nulls. I predict that these double knockout mice will be 
relatively sensitive to hypertrophy and the PI3K/Akt pathway will be activated 
compared with the Hdac2-/-. Similarly, Inpp5f transgenic mice can be crossed to 
Hdac2 transgenic mice to determine if the double transgenic mice are less susceptible 
to hypertrophic stimuli than the Hdac2 transgenic mice. 
 
4.2.4 Does Inpp5f function upstream of Akt? 
My results suggest that loss of Inpp5f leads to hyper-activation of the PI3K/Akt 
pathway upon stimulation while over-expression of Inpp5f results in down-regulation 
of the pathway activity in the heart. I performed Akt+/- and Inpp5f -/- crosses to 
address the question if Inpp5f really functions upstream of Akt in vivo. Future 
experiments can be done to analyze the double knockout phenotypes. I expect that the 
double knockout would be relatively resistant to hypertrophy compared with Inpp5f 
single nulls. 
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4.2.5 Does Gata4 need Friend of GATA (Fog) to recruit Hdac2? 
Most of the protein-protein interactions of GATA factors are mediated by its C-
terminal zinc finger, including the interaction with p300, Nkx2.5, NFAT, while the N-
terminal zinc finger interacts with Fog transcription factors (Pikkarainen et al., 2004). 
My study identifies the lysine rich domain located between the two zinc fingers as the 
region necessary for interaction with Hdac2. It is unknown whether this interaction is 
direct or requires other co-factors. Gata factors can recruit Hdacs to target genes, 
either by directly interacting or by associating with Fog (Friend of Gata) proteins that 
can recruit the NuRD complex containing Hdac1 and Hdac2 (Cantor and Orkin, 2005; 
Hong et al., 2005; Svensson et al., 1999; Tsang et al., 1997). The lysine rich domain 
we identified is very close to the region where Fog interacts with Gata. Therefore, it 
would be interesting to investigate if Gata4 requires Fog to interact with Hdac2. 
Several mutation screens have been done to identify point mutations in Gata-1 that 
disrupt binding to FOG-1 (Crispino et al., 1999; Crispino and Orkin, 2002) and these 
residues are highly conserved among all vertebrate GATA factors (Cantor and Orkin, 
2005). Experiments can be performed using in vitro translated Gata4 and Hdac2 
proteins to test if the interaction is direct or not. Co-IP can also be done in a Fog 
expressing cell line using mutated Gata4 that cannot recruit Fog and to see if the 
mutant Gata4 can interact with Hdac2 or not. 
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4.2.6 Can Hdacs deacetylate other Gata members? 
Other Gata family members have also been shown to recruit Hdacs to mediate 
transcriptional repression. For example, Hdac3 associates with and represses Gata2 in 
hematopoietic progenitor cells (Ozawa et al., 2001). Gata1 interaction with Hdac5 
results in reduced Gata1 transcriptional activity (Watamoto et al., 2003). In each case, 
Hdac function suppresses Gata dependent transcriptional activity. Although it was 
generally assumed that Hdac-mediated transcriptional repression of Gata activity was 
mediated by histone deacetylation and chromatin remodeling, it will be interesting to 
re-address this question in light of my results to determine if other Gata proteins are 
regulated by Hdacs via direct deacetylation. 
 
4.2.7 To what extent does Hdac2 regulates cardiomyocyte proliferation through 
Gata4 acetylation? 
In chapter 3, I showed that Hdac2 interacted with Gata4. Our lab also 
demonstrates that Hdac2 is able to deacetylate Gata4 and in Hdac2 null hearts Gata4 
acetylation is increased. Acetylated Gata4 has enhanced DNA binding and 
transcriptional ability (Takaya et al., 2008). Several studies have demonstrated a 
critical role for Gata4 in embryonic myocyte proliferation (Rojas et al., 2008; 
Zeisberg et al., 2005). All this evidence suggests that Hdac2 inhibits cardiomyocyte 
proliferation through deacetylating Gata4. However, we did not perform the definitive 
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experiments to test this concept. Future work could address this, by crossing Hdac2 
nulls with cardiac specific Gata4 nulls. We could expect the myocytes from double 
nulls have less proliferation rates than Hdac2 nulls. A cardiac specific Gata4 
acetylation deficient (by mutating lysine to alanine) knockin mouse model could also 
be generated. These mice can then be crossed with Hdac2 knockouts. Since the 
mutated Gata4 could not be acetylated, loss of Hdac2 would not lead to more myocyte 
proliferation. 
 
4.3 Concluding remarks 
The studies presented here define the mechanisms of Hdac2 in regulating 
embryonic heart development and adult heart hypertrophy. I identified two targets of 
Hdac2, Inpp5f and Gata4, and I investigated how they contribute to the phenotypes of 
Hdac2 nulls.  Hdac2 regulates Inpp5f through modifying the histones of its promoter 
while it regulates Gata4 through acetylating the Gata4 protein itself. The 
characterization of Hdacs and HATs and their various activities has attracted 
increasing investigative interest because of their importance in stem and progenitor 
cell biology and in cellular reprogramming. It would be exciting to see how these 
findings will contribute to the study of embryology to human medicine.  
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